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ABSTRACT 
WENDY CAMELO CASTILLO: Pharmacological treatment of gestational diabetes 
and association with adverse maternal and neonatal outcomes 
(Under the direction of Michele Jonsson Funk) 
Background:  In the United States, insulin is the only approved treatment for 
gestational diabetes (GDM). Glyburide has been used off-label as an alternative but 
there is still uncertainty regarding its safety and effectiveness in pregnancy.  
Purpose: 1) To identify trends and factors associated with use of glyburide, 
2) to estimate the association between glyburide and  adverse maternal or neonatal 
outcomes. 
Methods: We conducted a retrospective cohort study of commercially insured 
women with GDM with a pharmacy claim for glyburide or insulin 150 days prior to 
delivery, identified in an administrative claims database from 2000-2011. We 
excluded women <15 years or >50 years, with prior type 2 diabetes, or multiple 
gestations. We estimated trends over time in the use of glyburide versus insulin. 
Binomial regression was used to estimate prevalence ratios (PR) and 95% CI for the 
association between covariates of interest and treatment with glyburide.  We used 
inverse probability of treatment weights to adjust for confounding and binomial 
regression to estimate risk ratios (RR), risk differences (RD) and their 95% 
confidence intervals (CI). 
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Results: Among 9,180 women who met inclusion criteria, 54% were treated 
with glyburide. From 2000-2011, glyburide use increased steeply from 8.5% to 
64.5%. Women with metabolic syndrome (0.71 CI 0.50, 0.99) and hypothyroidism 
(0.89 CI 0.81, 0.97) were less likely to be treated with glyburide. After weighting, 
newborns from women treated with glyburide were at increased risk for NICU 
admission (1.39 CI 1.21, 1.59), respiratory distress (1.60 CI 1.21, 2.11), 
hypoglycemia (1.39 CI 1.00, 1.94), birth injury (1.36 CI 1.01, 1.84) and large for 
gestational age (1.43 CI 1.16, 1.76) compared to those treated with insulin. The 
absolute increase in risk in the glyburide group was 2.9% (CI 1.69, 4.00) for NICU 
admission, 1.4% (CI 0.60, 2.20) for large for gestational age and 1.1% (CI 0.46, 
1.68) for respiratory distress. 
Conclusions: Glyburide has replaced insulin as the preferred treatment for 
GDM over the last decade. Newborns from mothers treated with glyburide are more 
likely to experience adverse events. Identification of subgroups of women more likely 
to benefit from glyburide is a public health priority. 
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CHAPTER I- REVIEW OF THE LITERATURE 
1.1 Background and significance 
Management of gestational diabetes mellitus (GDM) is one of the major 
challenges that women and their obstetricians face during pregnancy. GDM is 
defined as glucose intolerance first recognized during gestation (1). Approximately 
2-10% of pregnant women  develop the condition with variations in its prevalence 
depending on the population and the definition used for diagnosis. Initial 
management of GDM as recommended by guidelines consists of dietary 
counselling, self monitoring of blood glucose and exercise (2). If initial management 
fails to achieve glucose control then pharmacological treatment should be 
considered. There is debate  regarding target glucose values should be achieved 
and there are no established guidelines for initiation of pharmacological treatment in 
women with GDM (3). 
Two randomized controlled trials (RCTs) have examined the effect of GDM 
treatment (with or without medication) on women with diagnosed GDM: the 
Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) (4) and 
the Maternal-Fetal Medicine Units Network trial (MFMU) (5). In both trials treatment 
included dietary recommendations, exercise and insulin if required, with a goal of 
maintaining fasting and postprandial glucose values below a defined cut point. 
Overall treatment proved to be beneficial in improving both maternal and neonatal 
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outcomes. Both studies showed a reduction of macrosomia (ACHOIS RR 0.62 
95%CI 0.34,0.64; MFMU 0.49 95%CI 0.32,0.76) and preeclampsia (ACHOIS RR 
0.70 95%CI 0.51, 0.95; MFMU RR 0.63 95%CI 0.42,0.96).The MFMU trial showed a 
reduction in the risk of shoulder dystocia (RR 0.37 95%CI 0.14, 0.97) while in the 
ACHOIS there seemed to be a protective effect which was not statistically significant 
(RR 0.46 95%CI 0.19, 1.10). Bone fracture and nerve palsy were not observed in the 
ACHOIS trial, while the MFMU trial did not ascertain these outcomes. None of the 
trials was able to assess risk of stillbirth, due to absence of outcomes. The risk of 
hypoglycemia, jaundice or respiratory distress syndrome did not differ between 
treatment groups in either trial. Approximately 8% of women in the MFMU and 20% 
of women in ACHOIS trial who received treatment required insulin therapy. 
Although these trials provided evidence of the beneficial effects of treatment, 
there is lack of agreement on how early treatment should be started, when 
pharmacological intervention is required and which pharmacological agents should 
be used. There is debate regarding which therapeutic class may be more beneficial 
in achieving glucose control and therefore preventing adverse events. 
1.2 Pharmacological treatment of GDM 
Even though insulin has been the treatment of choice, some European 
countries and South Africa have been using oral agents for many years (6, 7). 
Presently insulin is the only pharmacological treatment endorsed by ACOG (1) in the 
US, however UK NICE guidelines from 2010 have endorsed the use of glyburide as 
an alternative in suitable candidates (8). 
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The principles for pharmacological treatment in women with GDM have been 
discussed by Coustan and are based on three considerations: first, whether the 
medication crosses the placenta; second, if crossing the placenta how it affects the 
fetus; and third, if adequate glucose control can be achieved in the mother and thus 
prevent outcomes associated with hyperglycemia (9). Although human and NPH 
insulin have been the treatment of choice because they do not cross the placenta, 
glucose control is not always easily achieved and side effects occur, the most 
concerning being hypoglycemia (10). 
Some of the newer insulins such as the rapid acting insulins (lispro, Aspart 
and glulisine) and long acting insulins (detemir, glargine), can cross the placenta in 
animal models in a dose dependent manner (11, 12). Among women with pre-
gestational diabetes and GDM, rapid acting insulins do not appear to be associated 
with an increased risk of adverse effects and could provide better glucose control 
and less hypoglycemia compared to human insulin (10). Evidence for the efficacy of 
insulin glargine comes from pregnant women with type 1 or 2 diabetes, where 
glycemic control appears to improve when compared to short acting insulins. 
However there is insufficient data on its safety (13, 14). There are currently no data 
on insulin glulisine or detemir in pregnancy. 
In women with GDM, the need for multiple daily injections (2-3/day), ideal 
storage conditions, costs and intricacies of insulin therapy may compromise 
appropriate use and adherence to treatment. Given that GDM is a physiological 
state of insulin resistance, there has been debate on whether alternative therapies 
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that improve resistance would be more appropriate than insulin. In light of this, oral 
agents have been proposed as an alternative for women with GDM. 
The debate regarding the use of oral agents in pregnancy began when they 
became available on the market in the 1970s. They can be classified into three 
groups according to their mechanism of action: insulin secretagogues (those that 
stimulate insulin secretion), insulin sensitizers (which modulate insulin resistance) 
and α-glucosidase inhibitors (which affect glucose absorption) (15). The majority of 
research on safety and efficacy has been conducted on glyburide and metformin. 
The mechanism of action and ease of use of oral agents make them attractive 
for the population of pregnant women, but concerns regarding teratogenicity and 
potential for neonatal hypoglycemia have always been present. This was especially 
true for the first generation sulphonylureas which proved to be teratogenic in animal 
models (16). On the other hand, second generation drugs such as glyburide and 
metformin have a different profile. In Table 1 the drug classes, mechanism of action 
and evidence on safety of oral agents is presented. We will focus our discussion on 
glyburide and metformin since they are the two oral medications most commonly 
used for women with GDM. 
Glyburide 
The study by Langer in 2000 (17) was the first RCT to compare glyburide to 
insulin in women with GDM. Since then, two more RCTs (18, 19), several 
observational studies (20-22) and meta-analyses (8, 23) have compared the safety 
or effectiveness of the two drugs. In the studies reported in the meta-analysis by the 
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National Screening Committee, only five of the studies looked at congenital 
malformations: one had no outcomes in the insulin group, one found a lower risk in 
the glyburide group and in two the estimate was above the null for those on 
glyburide, although not statistically significant (8). Among those studies there is no 
agreement on which drug may be associated with a lower risk for maternal 
hypoglycemia, preeclampsia, macrosomia, and respiratory distress. There appears 
to be a higher risk of jaundice, neonatal hypoglycemia, and birth trauma associated 
with the use of glyburide although confidence intervals include the null. In both 
RCT’s and observational studies NICU stay was lower among those treated with 
glyburide. A limitation of all these studies was their sample size, with the largest 
study having only  ~250 women per group, yielding imprecise estimates (24). None 
of the trials ascertained obstetric trauma in the mother. 
Metformin 
Due to its mechanism of action, metformin appears to be an ideal choice for 
the treatment of GDM. Animal and experimental models have shown that metformin 
does cross the placenta and thus concerns about its effect on fetal metabolism have 
limited its use in pregnancy. Before 2008, a few small studies had compared the 
safety and efficacy metformin versus insulin in women with GDM. In the studies 
reported in the meta-analysis by the National Screening Committee, only one RCT 
and two observational studies ascertained congenital malformations; outcomes were 
observed only in two studies where there seemed to be a protective effect of 
metformin (8).  
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1.3 Adverse maternal and neonatal outcomes in women with GDM 
Overall, the goal of treatment whether pharmacological or not is to achieve 
glucose control. Previous studies like the Hyperglycemia and Perinatal Outcomes 
Study (HAPO) have showen that in women with elevated fasting and 1h, 2h or 3h 
glucose values, the risk of adverse outcomes increases proportionally to increasing 
glucose levels (25). Therefore higher glucose values at baseline may put women at 
elevated risks, independent of successful glucose control. However for some 
outcomes other risk factors, such as obesity, could directly affect outcome by 
modifying glucose control. In this section we will discuss the role of glucose control 
and other relevant factors in the risk of adverse maternal/neonatal outcomes in 
women who initiate pharmacological treatment. 
1.3.1 Maternal Outcomes 
Severe perineal trauma is defined as 3rd-4th degree perineal tears occurring 
during delivery. Third-degree tears are defined as a partial or complete disruption of 
the anal sphincter muscles, where fourth-degree tears involve the rectal mucosa 
(26). In women with severe perineal trauma, the risk of subsequent fecal 
incontinence is estimated to be up to 44% (27). Risk factors associated with trauma 
are assisted vaginal delivery, macrosomia and age (28, 29). 
1.3.2 Neonatal Outcomes 
During pregnancy, the most important factors that regulate glucose availability 
and insulin secretion in the fetus are maternal glucose control and placental function. 
The fetal pancreas begins insulin secretion as early as week 8-10 of development. 
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Secretion peaks during the last trimester and plays a critical role in fetal growth (30, 
31). In a normal pregnancy, glucose transport across the placental barrier will be 
equivalent to fetal demand (32). In GDM pregnancies, since glucose diffuses across 
the placental barrier by concentration gradient, glucose availability exceeds fetal 
demand, leading to increased secretion of insulin from the fetal pancreas. 
Depending on the level of hyperglycemia, this may lead to varying degrees of 
macrosomia, respiratory distress syndrome, polycythemia, or neonatal jaundice (33). 
At delivery, the persistence of increased insulin secretion in the neonate may put the 
neonate at risk for hypoglycemia (34). 
Macrosomia - Large for Gestational Age: These two terms refer to the 
newborns weight at birth but differ in their definition. Large for Gestational Age (LGA) 
is defined by neonatal birthweight above the 90th percentile (usually when weight is 
> 4000g, but may not be always the case) in a full term infant (35). By definition, up 
to 10% of newborns will be LGA. The diagnosis is made after delivery as current 
ultrasonographic methods are inaccurate for assessment of fetal size before birth 
(36). Macrosomia, refers to growth beyond a threshold which usually is between 
4000g- 4500g (37). Therefore while LGA uses as referent the distribution of birth 
weight on a given population, the cutoff for macrosomia is somewhat arbitrary. 
Regardless of the definition used, overgrowth in the neonate is associated with 
uncontrolled diabetes in pregnancy (pre-pregnancy or GDM)(25, 38), maternal 
obesity (39), high maternal weight gain during pregnancy, post-dates pregnancy 
(gestational age >41 wk), and a previous macrosomic newborn (37). Among women 
with diabetes in pregnancy, overgrowth can be prevented through adequate glucose 
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control. Besides the decreasing the risk of adverse outcomes associated with 
delivery, prevention of overgrowth may also prevent early delivery, cesarean section 
in the mother, and long term outcomes in the neonate such as metabolic syndrome 
and obesity (35). 
Metabolic –Hypoglycemia : Among the adverse neonatal outcomes 
associated with diabetes in pregnancy, the definition of neonatal hypoglycemia is still 
controversial. It can be defined by detection of low glucose values without 
associated symptoms (biochemical hypoglycemia <40 mg/dL), or by clinical 
manifestations (clinical hypoglycemia) (41). Additionally there is currently no 
consensus on the levels of hypoglycemia that are predictive of neonatal injury or the 
glucose threshold at which treatment should be started (34). Maternal and neonatal 
risk factors for hypoglycemia include preeclampsia, hypertension, diabetes, preterm 
birth, perinatal hypoxia/ischemia, fetal growth restriction and macrosomia (40). 
Medications used to attain glucose control during pregnancy can have effects on the 
fetus, either by affecting insulin secretion in the fetus (insulin or sulfonylureas) or by 
limiting glucose availability (metformin). 
Metabolic – Jaundice: Neonatal jaundice is defined as a yellowish tone of the 
skin secondary to elevated bilirubin in blood. The majority of bilirubin in serum is 
secondary to a turnover of red blood cells and degradation of hemoglobin. In 
neonates bilirubin levels are increased between the first 24-72h resolving in 1-2 
weeks, also known as physiological hyperbilirrubinemia, and is secondary to a 
higher red blood cell turnover and reduced hepatic clearance (41). However some 
newborns may experience an earlier or more sustained increase that can be caused 
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by pathological conditions or exaggeration of the normal ones. Particularly in women 
with diabetes, increased production of red blood cells in the newborn (polycythemia) 
may place them at risk for jaundice (42). Severe hyperbilirubinemia is associated 
with an increased risk for bilirubin induced neurologic dysfunction, which can cause 
severe long term impairment at the neurological level (43). Currently it is not known 
how glyburide (which is metabolized in the liver), and metformin (which appears to 
accumulate in red blood cells) may affect the metabolism of bilirubin in fetuses of 
women treated with these medications. 
Respiratory distress syndrome: Regardless of gestational age, respiratory 
failure in the neonate is a major cause of short and long-term morbidity and 
mortality, with its incidence decreasing with increasing gestational age (44). It is 
estimated that it could represent 30% of all admissions to neonatal intensive care 
unit (NICU) (45). Major risk factors are preterm delivery, diabetes during pregnancy, 
planned cesarean delivery and male gender. Vignoles et al examined the 
association between gestational diabetes and respiratory failure in neonates older 
than 34 weeks (46). After adjusting for late preterm birth, fetal growth restriction, 
gender and cesarean section, newborns from GDM mothers had a higher risk of 
respiratory failure (11.5 CI 95% 3.9-33.9). Although these findings have been 
described in infants born to mothers with type 1 or 2 diabetes, their incidence is less 
clear in women with GDM. Additionally different conditions may cause respiratory 
distress in the newborn (transient tachypnea, respiratory distress syndrome, 
meconium aspiration syndrome) (47). 
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Shoulder dystocia/birth injury: Both US and UK guidelines define shoulder 
dystocia as: ‘‘birth requiring additional obstetric maneuvers when gentle downward 
traction has failed to affect the delivery of the shoulders” (48). It is considered an 
obstetrical emergency with the potential to cause injury to the neonate and mother. 
The overall incidence of shoulder dystocia varies based on fetal weight, occurring in 
0.6 to 1.4% of infants with birth weight between 2,500g to 4,000g, increasing to a 
rate of 5 to 9% among those weighing 4,000 to 4,500g, born to mothers without 
diabetes (49, 50). 
Several factors have been associated with an increased risk for shoulder 
dystocia including gestational diabetes, obesity and previous shoulder dystocia a(51-
53). In diabetic mothers Langer et al showed that the rate of shoulder dystocia 
increased three-fold when the newborn weighs more than 4500g (51). Nevertheless 
it is largely unpredictable. Complications from shoulder dystocia affect both the 
mother and newborn. The most common maternal complications are postpartum 
hemorrhage and fourth-degree lacerations. In the infants the most common 
complication are neurological and orthopedic injury, specially brachial plexus injury. 
Tight control of glucose levels in pregnant women with diabetes may reduce the 
incidence of fetal macrosomia and shoulder dystocia (25). 
1.4 Summary 
In women with GDM in which achievement of glucose control cannot be 
attained through diet therapy and physical activity, pharmacological treatment is 
needed. Choices of pharmacological treatment are limited due to concerns regarding 
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potential placental transfer and effects on the fetus. Of all available drug classes, 
insulin is considered to be safest and it is the only medication approved by ACOG. 
However in recent years randomized controlled clinical trials have provided limited 
evidence on the safety of glyburide during pregnancy which has led to a widespread 
use in clinical practice. Because women with GDM and their newborns are at an 
increased risk of adverse outcomes, appropriate safe and effective therapy is key 
during pregnancy. 
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Table 1. Characteristics of oral agents used for treatment of GDM 
Class Drug Mec of Action Benefits 
Placental 
transfer 
Effect on 
the 
mother 
Effects 
on the 
fetus 
References 
Sulfonylureas Glyburide 
 
Improve post-prandial 
insulin secretion, best 
in patients with 
normal-increased 
weight. 
Minimal  
 
Indirect, 
due to 
glucose 
control 
(16, 17) 
Insulin 
sensitzers 
Metformin 
(Biguanides) 
Enhance insulin 
action, stimulating 
liver and peripheral 
uptake, 
suppressing liver 
glucose production 
Reduce insulin 
resistance, don't 
cause hyperglycemia. 
Used for PCOS*. 
Crosses 
barrier, fetal 
can be half of 
maternal 
concentrations. 
  Unknown 
(54, 55) 
TZD† 
Agonists of PPAR-
γ‡ receptor, found 
in target tissues for 
insulin action 
Reduce insulin 
resistance, don't 
cause hyperglycemia. 
Used for PCOS*. 
Crosses barrier 
at 10 wk of 
gestation, fetal 
can be half of 
maternal 
concentrations. 
Weight 
gain, fluid 
retention 
with 
edema  
Unknown 
(56, 57) 
α- 
Glucosidase 
Inhibitors 
Acarbose 
Slow the absorption 
of sugars in GI ǁ 
tract 
Decreases post meal 
peak 
Minimal 
absorption in 
GI† tract, 
placental 
transfer 
unknown  
Flatulence
, GI† 
discomfort 
Indirect, 
due to 
glucose 
control 
(57) 
†TZD- Thiazolidindiones; ‡ PPAR-γ- Peroxisome proliferator-activated receptor gamma *PCOS- Polycystic Ovarian 
Syndrome; ǁ GI – Gastrointestinal 
1
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 CHAPTER II-STATEMENT OF SPECIFIC AIMS 
2.1 Specific Aims 
Although glyburide is used as an alternative to insulin for women with GDM 
there is still insufficient evidence to support its use in pregnancy. Additionally, factors 
such as age, maternal comorbidities, and patient preference influence the choice of 
drug class used for treatment but the role of these factors is unknown. With this 
project our objectives are to identify the factors that drive choice of initial medication 
among women with GDM who require pharmacological treatment, and to understand 
how exposure to glyburide may affect the risk of adverse outcomes in both the 
mother and the newborn. 
In light of the unanswered questions regarding the comparative safety and 
effectiveness of glyburide relative to insulin, we propose to address the following 
aims: 
2.1a Specific Aim 1 
Aim: To characterize pharmacological treatment of women with gestational 
diabetes. 
2.1a1. Describe change in trends of use of oral agents and insulin therapies in 
women with gestational diabetes, from 2000-2011. 
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2.1a2. Identify predictors of treatment and describe treatment patterns during 
pregnancy among gestational diabetics. 
2.1a3. Describe blood glucose levels at time of diagnosis and their association with 
initiation and choice of treatment. 
Data for this analysis came from a cohort of women with GDM identified in the 
Truven MarketScan® Research Databases and Truven MarketScan® Lab 
Databases between January 1st, 2000 and December 31st, 2011.  
2.1b Specific Aim 2  
Aim: Estimate comparative safety and effectiveness of oral agents versus insulin on 
measures of adverse maternal and neonatal outcomes. 
Data for this analysis came from a cohort of women with GDM identified in the 
Truven MarketScan® Research Databases and Truven MarketScan® Lab 
Databases between January 1st, 2000 and December 31st, 2011.  
2.2 Hypotheses 
Based on GDM management guideline recommendations, we hypothesized that the 
proportion of women treated with glyburide would be lower than the proportion 
treated with insulin from 2000-2011. Additionally we expected a lower probability of 
being prescribed with glyburide among women with insulin resistance, especially 
those with obesity.  Due to the association between glucose values at baseline and 
severity of GDM, we hypothesized that women with higher fasting glucose values 
would less likely be prescribed with glyburide. 
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Using the results from RCTs as evidence we hypothesized that the rate of maternal 
and neonatal adverse events would not be different between women treated with 
glyburide when compared to insulin.    
 2.3 Rationale 
 With this study we seek to understand current practices in the 
pharmacological treatment of women with GDM. Although the use of glyburide is 
acknowledged by healthcare providers, little is known about the dissemination of 
glyburide use since the publication of the first RCT in 2000. From a public health 
perspective it is important to characterize current practices and to identify factors 
that influence choice of initial medication.  
Gestational diabetes puts women at higher risk of adverse maternal and 
neonatal outcomes. Measures to lower the risk include using medications to achieve 
glucose control in selected women. Due to their mechanism of action, ease of use 
and cost oral agents may be an appropriate first line treatment in this population. 
However evidence of safety from clinical trials is imprecise and this is partly due to 
their limited power to assess rare outcomes. On the other hand, the results from 
RCTs evaluating the effectiveness of oral agents versus insulin include populations 
with strict diet and glucose control which may not be reflective of usual care. Results 
from our study reflect real world use of these medications when compared to insulin 
and their impact on adverse outcomes. 
CHAPTER III-METHODS 
3.1 Data Source and Study Population 
The source of data for this project was Truven Health MarketScan® Research 
Databases. This database contains individual-level, de-identified, healthcare claims 
information from employees, spouses and dependents who are covered by employer 
sponsored private health insurance. It is one of the largest collections of employer 
and health plan based patient data in the U.S., with approximately 30 million lives 
annually from January 1st, 2000 to December 31st, 2011 covering all United States 
(U.S.) census regions(58). The database includes information on inpatient and 
outpatient medical claims, linked to outpatient pharmacy data and person level 
enrollment information. 
In addition to the commercial claims, we will be using the Truven Health 
MarketScan® Lab Database. This database captures results of laboratory tests for a 
subset of the covered lives (over 1 million) from 2007-2011, mainly representing 
those tests ordered in office-based practices. These results can be linked to the 
MarketScan® Research Databases. From our cohort of women with GDM diagnosis 
we will identify those with claims in the MarketScan® Lab Database. 
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3.2 Study Design 
We conducted a retrospective cohort study of women with a GDM diagnosis 
who initiated glyburide or insulin, identified in MarketScan® Research Databases 
from years 2000-2011. The index date was defined as the date of the first claim for 
glyburide or insulin during pregnancy.  
3.2.1 Identification of pregnancies 
We sought to identify women who had claims for delivery through the use of 
ICD-9 diagnosis, procedure and CPT codes (Appendix 1). Since a woman could 
have had more than one delivery, we grouped delivery claims occurring 
consecutively and defined them as separate pregnancy episodes if the last claim 
from the first episode was at least 45 days before the earliest claim from the second 
episode. The earliest delivery claim for each episode was defined as the delivery 
date. To identify events that occurred during pregnancy and at time of delivery, 
women were required to be continuously enrolled during the year prior to and at 
least three months after the delivery date (Figure 1).  
3.2.2 Identification of study population 
Clinically GDM is diagnosed when a pregnant woman meets one of the 
following criteria: 1) fasting plasma glucose between 92-126 mg/dl , or 2) positive 
oral glucose tolerance test (OGTT) at 24-28 weeks of gestation. If a woman has 
fasting plasma glucose ≥126 mg/dl, or a random plasma glucose ≥ 200 mg/dl any 
time before or during pregnancy she is considered to have pre-gestational diabetes 
An OGTT is not recommended in women with this diagnosis (59). Since lab values 
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are not available for the full cohort we based our definition of GDM on the use of 
ICD9 codes. 
For each pregnancy episode, we identified women who had a claim with a 
diagnosis code for GDM (ICD9 648.8-648.83) in the year prior to delivery. We 
excluded women 1) with diagnosis codes for type 1 or 2 diabetes, 2) under 15 years 
or over 50 years old, and 3) with diagnosis or procedure codes for pregnancy with 
multiple gestations. Our cohort was restricted to the first eligible GDM pregnancy for 
a given woman.  
3.2.3 Linkage to newborns 
Within the MarketScan® Databases, family members enrolled under the 
same plan share a common string in the identification number. Using the common 
string and year of birth, we probabilistically linked women in our cohort to children 
whose first claim occurred during the same calendar year as the maternal delivery 
code. To refine the linkage, we restricted the date of the potential newborn’s first 
claim to within 30 days of the delivery date. Some global payments could include in 
the maternal claims, billable services from newborn care at time of delivery. By 
extending the date of the first newborns claim up to 30 days after delivery we 
intended to capture newborns whose care was billed separately from their mothers, 
newborns who generated claims not covered by their mothers insurance (such as 
critical care or special procedures), or healthy newborns whose first claim would be 
a well-baby visit (which would only occur after delivery). This allowed us to capture 
not only sicker newborns that generated claims around time of the delivery but also 
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healthier newborns that would usually get an identification number at their first 
outpatient visit. To be able to ascertain use of health services we required newborns 
to be continuously enrolled up to three months after delivery date. 
3.2.4 Linkage to Laboratory Data 
Screening (50g), Baseline (fasting), 1h and 2h glucose values (mg/dl) were 
identified from the MarketScan® Lab Database through the presence of specific 
Logical Observation Identifiers Names and Codes (LOINC®). In the analysis both 
75g and 100gr glucose tolerance tests were included. Only the first occurrence for 
screening tests and OGTT was considered for the analysis. 
 3.2.5 Exposure 
We identified women in our cohort with a pharmacy claim for insulin or 
glyburide in the 150 days prior to delivery. Women who had a claim for insulin or 
glyburide earlier than 150 days prior to delivery were excluded from the analysis 
since use of these medications in early pregnancy is more likely to suggest pre-
pregnancy type 2 diabetes rather than GDM.  Those initiating pharmacological 
treatment after delivery were not included in this study. Classification as an insulin or 
glyburide initiator was based on the drug class of the first pharmacy claim identified 
for a given woman. 
3.2.6 Covariates 
Covariates of interest included maternal age at time of delivery (estimated by 
subtracting the year of birth from year of delivery), year of delivery, and maternal 
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comorbidities. Based on subject matter knowledge and consultation with experts we 
identified conditions associated with initiation of treatment or the outcomes of 
interest. All conditions were defined through the use of ICD-9-CM diagnosis code, 
CPT code or generic drug name. Comorbidities of interest were: infertility diagnosis 
(ICD9 V26.8, V26.81 CPT 89252, 89268, 89281, 58310, 58311, 58321-23, 58970-
76, 89250-57, 89268, 89272, 89280-81, 89290-91, 89352-54) or treatment (at least 
1 claim for clomiphene, urofollitropin, follitropin, menotropin, ganirelix, cetrorelix); 
obesity (ICD9 278.0X, 649.1X,V77.8, V85.3x, V85.4); hypothyroidism (ICD9 244.X); 
hyperandrogenism (defined as an ICD9 code for alopecia [704.0X] , hirsutism [ 
704.1] or acne [706.0, 706.1]); metabolic syndrome (ICD9 277.7); and polycystic 
ovarian syndrome (ICD9 256.4). Because metformin is used off label for infertility or 
to reduce risk of miscarriage we included history of metformin use as a covariate in 
the analysis. Etiologically it is not clear whether pregnancy induced hypertension 
and preeclampsia lead to GDM or viceversa. However both conditions are 
associated with adverse neonatal outcomes. To assess the role of pregnancy 
induced hypertension and preeclampsia, and avoid reverse causation, we identified 
women who initiated an antihypertensive or were hospitalized with a diagnosis code 
for preeclampsia (ICD9 642.40, 642.73) after initiation of pharmacotherapy. All other 
covariates were assessed in the time period prior to the index date (Figure 1). 
We also investigated regional differences in practice patterns - specifically, 
whether the use of glyburide versus insulin was different among rural/urban areas. 
We used Rural-Urban Continuum Codes to identify metropolitan, urban and rural 
counties(60) 
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3.2.5 Outcomes 
We defined maternal and neonatal outcomes as described in Table 2. These 
outcomes will be identified through ICD9 diagnosis, CPT and ICD9 procedure codes 
(Appendix  2 ). These codes were selected based upon previously published 
algorithms or guideline recommendations. 
3.3 Data Analysis 
3.3.1 Specific Aim 1 
Distribution of covariates was described using univariate and bivariate 
analysis. Exploratory analysis of maternal age as a categorical and continuous 
variable was undertaken prior to multivariate modeling. Because our assumption 
was that the association between age and choice of initial therapy would be non-
linear, we used fractional polynomials to account for this. We compared model fit 
between a predefined set of first degree fractional polynomial functions where the  
power of the function is set to -2, -1, -0.5, 0, 0.5, 1, 2, 3 (61). The function with the 
best fit was used in the multivariable model. Since fractional polynomial models are 
fit through maximum likelihood, the best-fitting model is selected based on which 
function yields the highest likelihood. 
Trends in the use of glyburide and insulin between years 2000-2011 were 
estimated by calculating the proportion of women on a given treatment, using as 
denominator the total number of women treated with medication in a given year. 
Binomial regression was used to adjust for covariates of interest. To estimate the 
annual percent change (APC) of glyburide use we used log-linear regression 
 22 
 
adjusted for age and covariates of interest. The slope is exponentiated to calculate 
the percent change per year. The underlying assumption is that the rates are linear 
on the logarithmic scale. Because trends of glyburide use could be non- constant 
over the 2000-2011 period we estimated average annual percent change (AAPC). 
AAPC summarizes the trend over a sub-period of interest and allows identification of 
transitions in the trend. We identified intervals in which the trend was linear and 
estimated the APC. The AAPC over any fixed interval is a weighted average of the 
slope coefficients of the APC with the weights equal to the length of each segment 
over the interval(62). 
We used binomial regression to estimate prevalence ratios (PR) and 95% 
confidence intervals (CI) for the association between baseline characteristics (age, 
comorbidities, calendar time) and treatment with glyburide versus insulin.  
To assess whether glucose levels at the time of GDM diagnosis influenced 
the choice of medication, we compared the distribution of screening, fasting, 1 and 2 
hour post-test glucose values between treatment groups. We estimated the effect of 
blood glucose values at baseline on the probability of being prescribed glyburide 
versus insulin using binomial regression.  Glucose values were modeled as 
continuous variables. We used multivariable regression with generalized estimation 
equations to account for correlation between glucose tests.  
3.3.2 Specific Aim 2 
We used logistic regression to calculate the probability of treatment with 
glyburide compared to insulin, adjusting for all covariates. The distributions were 
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examined to identify areas of non-overlap between treatment groups. Age and 
comorbidities were included in the model. To add flexibility to the model we also 
included squared terms for age. This propensity score was then used to create 
stabilized inverse probability of treatment weights (IPTW) to adjust for confounders 
in the risk model (63). Balance of measured confounders after estimating the 
propensity scores and distribution of the IPTWs was assessed.  
Binomial regression with a log link was used to estimate risk ratios and risk 
differences. Robust variance was used to estimate 95% confidence intervals (RR 
95%CI and RD 95%CI, respectively) for the association between glyburide and 
adverse outcomes. Risks were estimated using a weighted model adjusted for 
calendar year, using dummy variables, to account for changes in treatment over the 
11 year period.  
3.3.2.1Sensitivity Analysis 
Because glyburide uptake occurred mostly between 2004-2006, we 
conducted sensitivity analysis to estimate the potential effect that early adopters of 
therapy could have on our estimates.  Additionally because ICD9 codes for body 
mass index (BMI) were introduced after 2007, we were also interested in assessing 
the effect of the introduction of these codes on the ascertainment of obesity, which is 
a potential confounder in this setting. To assess this, we created three sub-cohorts 
that excluded women who:  a) entered the cohort before 2004 (early adopters), b) 
entered before 2005 (transition period for glyburide uptake), c) entered before 2007.  
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Because our data lack information on BMI and we rely on the use of ICD9 
codes to ascertain obesity, under ascertainment of this variable is possible. To 
investigate the impact of residual confounding we used the array approach 
developed by Schneeweiss (64). Given that this approach was developed to 
evaluate unmeasured confounding, we estimated the effect of glyburide and adverse 
outcomes that would have been observed when excluding obesity from our adjusted 
model. In this scenario we assessed how imbalance of obesity between glyburide 
and insulin groups could bias the observed estimates of association.  
3.3.3 Software and approval 
All analyses were conducted using SAS v 9.3 (SAS Institute, Cary, NC).  The 
Institutional Review Board (IRB) at the University of North Carolina, Public Health –
Nursing IRB, Office of Human Research Ethics provided approval for this study. 
  
 25 
 
3.4 Tables and Figures 
 
Table 2. Outcome definitions 
 
 Condition Definition Ref 
Maternal 
Perineal 
trauma 
(severe) 
≥1 claim with code for 3rd or 4th 
degree perineal laceration occurring 
during birth 
(65) 
Neonatal 
 
NICU 
admission 
≥1 claim with code for intensive care 
unit admission > 24 h 
Code not 
validated 
Respiratory 
distress 
syndrome 
≥1 claim associated with admission to 
NICU with ICD9 diagnosis code, 
excluding transient tachypnea 
(66) 
Hypoglycemia 
≥1 claim associated with admission to 
NICU with ICD9 diagnosis code for 
neonatal hypoglycemia.  
(66) 
Jaundice 
≥1 claim associated with admission to 
NICU with code for 
hyperbilirubinemia not associated to 
hemolytic disease. Also includes 
neonates with CPT or ICD9 
procedure codes phototherapy or 
exchange transfusion. 
(67) 
Shoulder 
dystocia/birth 
injury 
≥1 claim with ICD9 diagnosis code for 
fetal disproportion, shoulder dystocia, 
or fetal injury (scalp, fracture) 
(68) 
Preterm 
≥1 neonatal claim with ICD9 code for 
preterm birth 
(69) 
Large for 
Gestational 
Age 
≥1 claim with ICD9 diagnosis code for 
large for gestational age 
Code not 
validated 
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Figure 1. Index date and ascertainment of baseline  
 
 
 
 
 CHAPTER IV-GENERAL RESULTS 
 
This chapter presents general results of this study not presented in the 
manuscripts. It will focus on characteristics of the cohort selection process, linkage 
to newborns and laboratory data, comparison of glucose distributions across 
treatment groups and results from the propensity score and IPTW analysis. 
4.1 Cohort Selection 
A flow diagram for the cohort selection process is presented in Figure 3. After 
applying the continuous enrollment criteria, 45% (N=1,018,383) of women with a 
delivery remained in the cohort. Of those, 13% were identified as having GDM and 
meeting inclusion criteria. Among these we identified 14,558 women with a claim for 
insulin or glyburide.  
4.2 Linkage to newborns and laboratory data 
Overall, we were able to link 82% (N=110,879) of women with GDM with a 
corresponding newborn (Table 3). Non linkage can be attributed to newborns being 
under the insurance of a father whose claims are not in the database or newborns 
who do not generate claims (such as stillborns). Of those with medication, 9,180 
(63%) had a claim for insulin or glyburide with an index date within 150d before 
delivery. This final group was considered as the analytical cohort. 
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Laboratory data from Truven Health MarketScan® Lab Database was 
available for 6.1% (N=6,776) of women with GDM with linkage to a newborn (Table 
3). Of the ones who initiated pharmacotherapy only 57.3% (N=359) had lab values 
for screening or any of the tests within the OGTT (fasting, 1hour or 2 hour tests). 
Reasons for missing laboratory data could be related to more billing for these 
services where the lab was done. Because our dataset includes claims billed by a 
single provider, if a woman was seen in a facility with a clinical laboratory those 
claims would not be captured in the database. 
4.3 Comparison of distribution of glucose values between treatment groups 
Figure 3 shows the distributions of the screening, fasting, one hour and two 
hour glucose tests for women with laboratory results in the database. Overlap 
between treatment groups is observed across the four tests.  
4.4 Propensity Score distributions and IPTWs 
Before applying the propensity score, there was evidence of imbalance in 
several of the covariates between the glyburide and insulin groups. In Figure 4 we 
observe the distribution of the propensity scores where there was considerable 
overlap between the two distributions, reflective of achieved balance of measured 
confounders. The majority of individuals had propensity scores between 0.5 and 0.6. 
After stabilizing IPTWs we observed a mean value of 1.0 in each treatment group 
with a maximum value of 1.5634 and 1.7720 in the insulin and glyburide groups 
respectively. No trimming was performed. 
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4.5 Tables and Figures 
Table 3. Number and proportion of women linked to newborns and to laboratory data, 2000 -
2011 
  
Linkage to Newborn 
  
  
Yes 
 
No 
 
Total 
  
N % 
 
No % 
  
GDM 
No 
Medication    98,605  82.1 
 
   21,533  17.9 
 
   
120,138  
Medication    12,335  84.7 
 
      2,223  15.3 
 
     
14,558  
Total  110,940  82.4 
 
   23,756  17.6 
 
   
134,696  
         
GDM 
+ Lab 
No 
medication       6,150  73.9 
 
      2,168  26.1 
 
      
8,318  
Medication          626  75.3 
 
         205  24.7 
 
           
831  
Total       6,776  74.1 
 
      2,373  25.9 
 
       
9,149  
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Figure 2. Flow diagram for cohort selection 
 
All women with Delivery Claim 
N=2,235,437 
Women with RX within 150d prior to 
delivery 
N=9,194 
Women with linkage to newborn 
N=12,335 
Women with continuous enrollment from 
365d prior, to 90d after delivery  
N=1,018,383 
Women with GDM diagnosis code 
N=153,164 
Women with medication 
N=14,558 
Women with inclusion criteria 
N=134,696 
Women prescribed with glyburide or 
insulin 
N=9,180 
Prescribed with other drug 
classes 
N=14 
Initiation of RX prior to 150d 
before delivery 
N=2,235,437 
Without linkage to newborn 
N=2,223 
Exclusion: 
 Diabetes type1 or 2 
 Multiples 
 Age <15 or >50 
N= 18,468 
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Figure 3. Comparison of distribution of glucose values for screening, fasting, one hour and two hour tests in women with laboratory 
data. 
A. Screening B. Fasting 
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C.One Hour D. Two Hour 
  
 
Distribution of glucose values from screening and OGTT at baseline. Blue- Glyburide; Red- Insulin  X axis represents 
glucose in mg/dl, Y axis represents densities. Vertical line- American Diabetes Association (ADA) cutoff values for 
diagnosis of GDM. 
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Figure 4. Overlap between propensity score distributions of women treated with glyburide or insulin . 
 IPTW 
 
 Insulin Glyburide 
Mean 1.00 1.00 
SD 0.09 0.07 
Max 1.56 1.77 
Min 0.69 0.72 
q_0 0.66 0.72 
q_25 0.97 0.99 
q_50 0.99 1.01 
q_75 1.01 1.03 
q_95 1.20 1.11 
q_100 1.56 1.77 
 
 
Blue- Glyburide; Red- Insulin. Right table -Characteristics of the IPTW distributions  
 
 
 
CHAPTER V- MANUSCRIPT 1 
 
Trends in Glyburide or Insulin Use for Treatment of Gestational Diabetes in the U.S., 
2000-2011 
5.1 Introduction 
The prevalence of gestational diabetes mellitus (GDM) in the United States 
more than doubled from 1.5% in 1989-1990 to 4.2% 2001-2004, with varying 
prevalence rates from 5-8% across regions (70, 71). Over the last decade a 
substantial fraction of diagnosed women require pharmacologic treatment during 
pregnancy. Currently the only FDA-approved medication for the treatment of GDM is 
insulin (72) although glyburide (an oral agent), is also used (73).  
Glyburide is a second generation sulfonylurea, thought to be effective for the 
treatment of GDM because this condition is characterized by an early phase of 
insulin resistance followed by a decrease in the pancreatic β-cell insulin response 
(74). Glyburide is believed to be safe because of animal and in-vitro placental 
studies showing minimal transfer (75, 76), although recent studies in humans have 
shown that umbilical cord concentrations can be 70% of those found in maternal 
plasma (77).  Its ease of use and low cost is an additional advantage when 
compared to insulin which is administered by injection and entails higher costs. 
In 2000, Langer et al. conducted the first randomized controlled trial (RCT) 
comparing glyburide to insulin in 404 women with GDM (17). Since then, two more 
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RCTs (18, 19), some observational studies (20, 21, 24) and meta-analyses(8, 23) 
have compared the safety or effectiveness of the two drugs it is unknown how 
evidence from these studies has affected choice of medication in routine practice 
and which factors influence the prescription of glyburide versus insulin.  
Our objective was to characterize pharmacological treatment of women with 
GDM by describing trends in the use of glyburide and insulin over the last decade, 
and identifying predictors of treatment choice. 
5.2 Results 
Of 110,940 women with an eligible GDM pregnancy linked to a newborn, 
9,180 (8.2%) had a pharmacy claim for insulin or glyburide during the 150 days prior 
to delivery (Table 4). The median age at baseline was 33 years (interquartile range 
30-37). Glyburide was prescribed as the initial medication for approximately half of 
pregnancies overall (54.3%, N=4,986). The use of glyburide was less common in the 
Northeast (45.1% vs 54.9%) and slightly more common in the South (56.1% vs 
44.7%) and Northcentral (55.4% vs 44.6%) regions of the US.  
The use of glyburide increased steeply from 9.2% in 2000 to 64.4% in 2011. 
When comparing glyburide to insulin, the adjusted annual percent change was 
higher  between 2000-2007 (31.6% 95%CI 17.8, 46.9) and reached a plateau after 
2008 with an annual increase of 3.2% (95%CI 0.1, 6.5). The probability of being 
prescribed glyburide varied by age with a 5% decrease for every 10 year increase in 
age (PR 0.95, 95%CI 0.91,0.99) (Figure 5).  
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The proportion of women with comorbidities was generally similar between 
treatment groups, although those who were treated with glyburide were less likely to 
have a history of infertility treatment (PR 0.93, 95%CI 0.86, 1.02), PCOS (PR 0.88, 
95%CI 0.78, 0.99), or hyperandrogenism (PR 0.77, 95%CI 0.62, 0.97) (Table 5). In 
women with obesity, there was no preference for one treatment over the other (PR 
1.04 95%CI 0.98, 1.10). Women with metabolic syndrome and hypothyroidism were 
less likely to be treated with glyburide (PR 0.71, 95%CI:0.50, 0.99; PR  0.89 95%CI 
0.83, 0.96, respectively). Prior metformin use was not associated with initiation of 
glyburide (PR 1.01 95%CI 0.94, 1.09).  
Lab results were available from the MarketScan Lab Database® for 3.7% 
(N=339) of the cohort. Sixty six percent of women with lab values were in the 
glyburide group (N=224). When compared to the full cohort, women in the 
subsample were slightly older (median age 35 years, interquartile range 31-38) and 
obese (19.1%  and 18.8% respectively for insulin and glyburide groups). Women in 
the insulin group had a higher prevalence of hypothyroidism (13.0%). For differences 
in baseline covariates for the subgroup with lab results, refer to Appendix 3.  We 
compared the distributions of the earliest 50g screening, fasting, 1 hour and 2 hour 
blood glucose tests for women initially treated with glyburide or insulin. Results are 
presented as [mean (SD)]. Although the distributions for the two groups were similar 
for screening and 2 hour glucose values, the fasting values were slightly higher for 
those initiating glyburide [92.4 (10.9)] when compared to insulin [ 90.9(12.2)]. The 1 
hour test results were more similar between treatment groups (glyburide 
[193.7(25.6)]; insulin group [192.1(24.2)]). For every 10 unit change in two-hour 
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glucose values, the probability of being prescribed with glyburide increased by 2% 
(PR= 1.02 95%CI 0.97, 1.08) (Table 6).  
5.3 Discussion 
We found a marked increase in the use of glyburide over the period of 2000-
2011 with a corresponding decrease in insulin as first line of therapy which 
correlates with the publication of results from randomized clinical trials (17-19) and 
observational studies (20, 21, 24, 78). Our results support findings from recent 
studies showing widespread use of glyburide despite lack of conclusive clinical 
guidelines being available (79, 80). 
Among the comorbidities of interest we did not find strong predictors for 
initiation of glyburide. Women with infertility, PCOS and hyperandrogenism were 
more likely to be treated with insulin as were those with hypothyroidism or metabolic 
syndrome. Interestingly women with an ICD9 code for obesity were equally likely to 
be prescribed with glyburide versus insulin. In obese women, factors other than 
insulin resistance, such as concerns associated with increased weight gain and 
distribution of insulin at injection site could be drivers of initiation of treatment with 
glyburide (81).  Because insulin resistance is the common denominator in all these 
conditions, the degree of perceived insulin resistance could be an additional driver of 
initial choice of treatment for GDM. 
In non- pregnant populations, thiazolidinediones and metformin are used to 
improve insulin sensitivity among individuals with type 2 diabetes.  
Thiazolidiendiones are contraindicated in pregnancy, and metformin crosses the 
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placenta and therefore its use in pregnancy is not recommended in the U.S (82). 
Currently metformin is used in the pre-conception period to improve insulin 
sensitivity among women with insulin resistance who want to conceive (83, 84). Our 
findings reflect this where a large proportion of women treated with metformin in 
early pregnancy had a diagnosis of PCOS (39% [n=205]), or were treated for 
infertility (26% [n=134]).  
Little is known about the role of age on the preference to initiate treatment 
with oral agents among women with GDM.  It is known that the risk for developing 
GDM as well as severity of the disease increases with age. In our study, 41% of 
women were older than 35 years which reflects the increase in the pregnancy rate 
among this population over the last decade (85). Among those with GDM, the 
probability of being prescribed glyburide decreased by 5% for every 10 year 
increase in age. On the other hand after the dissemination of glyburide use, younger 
women were more likely to be prescribed with the oral agent after 2007 (Figure 5). 
This provides evidence that age can be influential on the decision of which drug 
class to initiate. 
Distributions of screening, one hour fasting and two hour glucose values at 
baseline were similar between the treatment groups. Glucose distributions have 
previously been described for treated versus untreated women with GDM, but not for 
women who initiated treatment (86). Although studies such as the Hyperglycemia 
and Adverse Outcomes in Pregnancy (HAPO) have shown that the risk of adverse 
maternal and neonatal outcomes is associated with increasing values of fasting 
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glucose at baseline, the role of these values in determining which pharmacotherapy 
to initiate is less certain (86).  
It is important to note that there were differences between the study cohort 
and the sample with lab values in their baseline covariates. The sample had a higher 
proportion of obese and hypothyroid women, more so among those initiating insulin. 
After adjusting for comorbidities, two- hour glucose values could be slightly 
associated with type of medication. For every 10 unit increase in their fasting 
glucose values women were 2% more likely to be prescribed with glyburide. Fasting 
and one- hour  values were not associated with choice of initial prescription. Glucose 
values before initiation of treatment may have a stronger association with choice of 
pharmacotherapy.  
Some of the limitations of this study are absence of gestational age or 
information on last menstrual period, biometrics (weight or height) and race-ethnicity.  
Although we cannot identify the beginning of pregnancy in our cohort, we believe our 
definition of GDM in combination with the exclusion of women who had early 
pharmacy claims for the drugs of interest yields a cohort of ‘true’ gestational 
diabetics. This approach has been validated by Andrade et al where they found a 
PPV of 85% (95%CI 71-94%) (28). Although BMI is the gold standard to classify 
women as obese, we were limited to the use of ICD9 codes to identify this condition. 
In their study, Andrade et al validated the use of ICD9 codes for obesity and 
reported that positive predictive value was high (92% 95%CI 90-94) but sensitivity 
was low (33%) (87). This suggests that there is considerable under-reporting of 
obesity based on ICD-9 diagnosis codes, but, we do not expect this to be differential 
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between the drug classes of interest. A further limitation of ICD9 codes in this setting 
is the ability to identify women who are overweight, where in this subgroup 
preference for glyburide could be different.  
Absence of race and ethnicity is a limitation of our study. Previous population 
based studies have shown that GDM prevalence is higher among certain racial 
groups such as Hispanics, Asians and Native Americans (88). Regarding initiation of 
pharmacotherapy, Berggren et al have reported differences were Hispanics were 
more likely than African Americans or Whites to receive glyburide or insulin (89). 
However this may not be unrelated to other factors such as access to care or low 
socioeconomic status among others. Since the purpose of this study is to provide an 
overview of glyburide use addressing racial differences is beyond the scope of this 
study. This cohort is representative of an insured, employed population and the 
results from this study may not be applicable to other populations. 
Strengths of the study include sample size and ascertainment of medication 
use. Our cohort was selected from a large and nationally representative population 
of women with gestational diabetes who were pharmacologically treated over a 11 
year period. When compared to previous studies only 8.3% of women with a GDM 
diagnosis in our study required pharmacological treatment. This contrasts with 
studies reporting prevalences that range between 8-43% (4, 5). However there are 
important differences in terms of the population due to severity of GDM, and 
generalizability (trials or hospital based populations). Our study likely includes 
women with different degrees of severity and is reflective of the full spectrum of 
patients treated across a range of clinical settings.  By restricting our cohort to 
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women who were continuously enrolled in the year prior to delivery we assured that 
use of healthcare and pharmacy services would be observable throughout 
pregnancy. Therefore medication use in our study is based on pharmacy claims of 
dispensed drugs which allowed us to identify the earliest prescription in pregnancy. 
When compared to self-report, by using pharmacy claims we have better 
ascertainment of initiation of treatment during pregnancy. 
Conclusion 
Dissemination of glyburide for the pharmacological treatment of GDM has 
been rapid and our findings indicate that it has become the preferred choice for initial 
treatment, particularly among younger, non-insulin resistant women. When 
compared to insulin, glyburide has important advantages such as ease of use and 
costs, which can influence patient and provider preference (90).  Since glyburide 
appears to have replaced insulin as the preferred treatment for GDM over the last 
decade, robust evaluation of glyburide’s relative and effectiveness is warranted to 
inform treatment decisions for women with gestational diabetes. Given the short and 
long term implications of suboptimal glucose control in women with GDM, assessing 
the effectiveness of glyburide versus insulin is a clinical and public health priority. 
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5.4 Tables and Figures 
Table 4. Characteristics of women diagnosed with GDM who initiate medication, 15-50y in a 
US based population, 2000-2011 
 
Insulin 
 
Glyburide 
 
 
N=4,194 % 
 
N=4,986 % %Δ* 
Age, year- Mean(SD) 34 (4.7) 
  
33 (4.7) 
  Age, 5y categories 
      15-19 4 0.1 
 
3 0.06 -0.04 
20-24 99 2.4 
 
124 2.5 0.13 
25-29 730 17.4 
 
940 18.9 1.45 
30-34 1593 38.0 
 
1860 37.3 -0.68 
35-39 1292 30.8 
 
1508 30.2 -0.56 
40-44 442 10.5 
 
523 10.5 -0.05 
>=45 34 0.8 
 
28 0.6 -0.25 
Calendar year 
      2001 54 1.3 
 
5 0.1 -1.19 
2002 115 2.7 
 
20 0.4 -2.34 
2003 245 5.8 
 
73 1.5 -4.38 
2004 366 8.7 
 
188 3.8 -4.96 
2005 449 10.7 
 
306 6.1 -4.57 
2006 409 9.8 
 
374 7.5 -2.25 
2007 406 9.7 
 
538 10.8 1.11 
2008 438 10.4 
 
661 13.3 2.81 
2009 657 15.7 
 
1003 20.1 4.45 
2010 563 13.4 
 
928 18.6 5.19 
2011 492 11.7 
 
890 17.8 6.12 
Region 
      Northeast 639 15.2 
 
525 10.5 -4.71 
Northcentral 1163 27.7 
 
1442 28.9 1.19 
South 1529 36.5 
 
1955 39.2 2.75 
West  838 20.0 
 
1037 20.8 0.82 
Unknown 25 0.6 
 
27 0.5 0.05 
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Insulin 
 
Glyburide 
 
 
N=4,194 % 
 
N=4,986 % %Δ* 
Urbanity† 
      Metro 3142 87.4 
 
3,453 88.2 0.87 
Urban  399 11.1 
 
412 10.5 -0.57 
Rural 36 1.0 
 
39 1.0 0.00 
Unknown 19 0.5 
 
9 0.2 -0.30 
Comorbidities 
      Infertility treatment 283 6.7 
 
280 5.6 -1.13 
Hypothyroidism 349 8.3 
 
353 7.1 -1.24 
PCOS‡ 171 4.1 
 
162 3.2 -0.83 
Hyperprolactinemia 14 0.3 
 
11 0.2 -0.11 
Hyperandrogenism 67 1.6 
 
99 2.0 0.39 
Metabolic syndrome 30 0.7 
 
20 0.4 -0.31 
Obesity 305 7.3 
 
499 10.0 2.74 
No comorbidities 3154 75.2 
 
3773 75.7 0.47 
Metformin use 
      Any use before 1st Rx 283 6.7 
 
317 6.4 -0.39 
 
 
*Difference in percentage (Δ%)-Estimated by subtracting percentages in insulin 
column from glyburide. †Urbanity – FIPS county codes were available for women in 
the 2000-2010 period (Glyburide N=3,596; Insulin N=3,913). PCOS- Polycystic 
Ovarian Syndrome 
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Table 5. Association of calendar year and maternal characteristics with initiation of glyburide 
vs insulin. Crude vs Adjusted* Prevalence Ratios (95% Confidence Interval)  
 
Crude  
 
Adjusted 
 
PR 95%CI 
 
PR 95%CI 
Calendar year 
     2001 0.13 0.06, 0.30 
 
0.13 0.06, 0.30 
2002 0.23 0.15, 0.35 
 
0.23 0.15, 0.34 
2003 0.36 0.29, 0.44 
 
0.35 0.29, 0.44 
2004 0.53 0.47, 0.60 
 
0.52 0.46, 0.59 
2005 0.63 0.57, 0.69 
 
0.63 0.57, 0.69 
2006 0.74 0.68, 0.81 
 
0.74 0.68, 0.80 
2007 0.88 0.83, 0.95 
 
0.88 0.82, 0.94 
2008 0.93 0.88, 0.99 
 
0.93 0.88, 0.99 
2009 0.94 0.89, 0.99 
 
0.93 0.88, 0.99 
2010 0.97 0.91, 1.02 0.96 0.91, 1.00 
2011 1.00 
  
1.00 
 Age 10y Change  
(Continuous) 0.96 0.93, 1.00 
 
0.95 0.91,0.99 
Comorbidities 
     Infertility treatment 0.91 0.84, 0.99 
 
0.93 0.86, 1.02 
Hypothyroidism 0.92 0.85, 0.99 
 
0.89 0.83, 0.96 
PCOS 0.90 0.80, 1.00 
 
0.88 0.78, 0.99 
Hyperandrogenism 0.80 0.64, 1.00 
 
0.77 0.62, 0.97 
Metabolic syndrome 0.74 0.52, 1.03 
 
0.71 0.50, 0.99 
Obesity 1.16 1.09, 1.23 
 
1.04 0.98, 1.10 
Metformin use 
     Any Use 1.00 0.92, 1.07 
 
1.01 0.94, 1.09 
 
*All prevalence ratio estimates were adjusted for all other variables in the table.  
†Reference category 
‡PCOS- Polycystic Ovarian Syndrome 
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Table 6. Association of glucose tolerance test results and initiation of glyburide. Prevalence 
Ratios (95%Confidence Intervals) for 10 unit change in glucose values.  
 
 
Crude  
 
Adjusted 
 
PR 95%CI 
 
PR 95%CI 
Screening 1.00 0.95, 1.05 
 
1.01 0.96, 1.07 
Fasting 1.00 0.90, 1.11 
 
1.00 0.90, 1.10 
One Hour 0.99 0.93, 1.05 
 
0.98 0.92, 1.04 
Two Hour 1.02 0.96, 1.07 
 
1.02 0.97, 1.08 
 
 
Prevalence Ratios (PR) were estimated from multivariable Binomial regression analyses, 
mutually adjusted for  age and maternal comorbidities (hypothyroidism, obesity) .PR were 
estimated in a subsample of the full cohort [Glyburide (N=224 ), Insulin (N=115)] 
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Figure 5. Trends of glyburide prescribing, by age group. Proportions were estimated from 
multivariable Binomial regression analyses, adjusted for all maternal comorbidities and prior 
metformin use. 
 
 
 
 
 
CHAPTER VI- MANUSCRIPT 2 
 
Effectiveness Of Glyburide Versus Insulin On Measures Of Adverse Maternal And 
Neonatal Outcomes in women with Gestational Diabetes 
6.1 Introduction 
The prevalence of gestational diabetes (GDM) in the United States (US) has 
more than doubled over the last 20 years (70, 71).  Because uncontrolled 
hyperglycemia during pregnancy affects fetal development and neonatal adaptation, 
adequate treatment has a direct impact in preventing adverse maternal and perinatal 
outcomes (4). In 7-10% of women with GDM, routine care such as dietary measures, 
physical activity and glucose monitoring may not be enough to achieve glucose 
control. In this group, initiation of pharmacotherapy becomes the next step but 
evidence on the safety and effectiveness of available therapies is still scarce. 
Insulin is the only pharmacological treatment endorsed by the American 
Diabetes Association (72) for the treatment of GDM in the United States (US). Due 
to its mechanism of action, ease of use and cost glyburide may be an appropriate 
first line treatment alternative. The study by Langer et al. in 2000 (17) was the first 
randomized controlled trial (RCT) to provide evidence on the efficacy of glyburide 
versus insulin in women with GDM. Since then two more RCTs (18, 19), several 
observational studies (20, 24, 91, 92) and meta-analyses (8, 23) have been 
conducted. Evidence from trials suggests that glyburide may be associated with poor 
outcomes such as neonatal jaundice, hypoglycemia and birth trauma. Less studied 
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outcomes have been large for gestational age and respiratory distress. Given its 
widespread use and rapid uptake of glyburide in the last decade, further evaluation 
of the association between adverse neonatal outcomes and use of glyburide is 
needed. The purpose of this study was to assess the effectiveness of glyburide 
compared to insulin in the treatment of gestational diabetes in a real world 
population. 
6.2 Results 
We identified 110,940 women with GDM and their babies, of whom 8.3% 
initiated pharmacotherapy. There were 4,986 (54.3%) women treated with glyburide 
and 4,194 treated with insulin. Characteristics of women at baseline appear in Table 
1. The mean age was 33.5 [SD 4.7] years. The proportion of women treated with 
glyburide increased from 8.5% in 2000 to 64.4% in 2011. Obesity and preeclampsia 
were more common in the glyburide group, while hypothyroidism and infertility 
treatment were more common in women treated with insulin. There were no 
differences between groups in metformin use prior to the initiation of 
pharmacotherapy (Table 7). 
Table 8 shows the crude and adjusted results for the risk of adverse maternal 
and neonatal outcomes in women initiated with glyburide when compared with 
insulin. We observed an increased risk of NICU admission (RR 1.39 95%CI 1.21, 
1.59), respiratory distress (1.60 95%CI 1.21, 2.11), neonatal hypoglycemia (1.39 
95%CI 1.00, 1.94), birth injury (1.36 95%CI 1.01, 1.8) and large for gestational age 
(1.43 95%CI 1.6, 1.76) among newborns whose mothers were treated with 
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glyburide. The risk of cesarean section was 3% lower in the glyburide group (RR 
0.97 95%CI 0.93, 1.00). The absolute increase in risk was higher for admission to 
NICU (RD 2.9 95%CI 1.7, 4.0), large for gestational age (RD 1.4 95%CI 0.6, 2.2) 
and respiratory distress (RD 1.1 95%CI 0.5, 1.7) (Table 3). The corresponding 
numbers needed to harm were 35 (95%CI 25,59) for NICU admission, 71 (95%CI 
46,165) for large for gestational age, and 94 (95%CI 59,220) for respiratory distress. 
We conducted secondary analysis excluding women treated before 2004, 
2005 or 2007 (Appendix 4).  We chose these cutoffs based on the trends of use of 
glyburide reported by Camelo-Castillo et al. (REF PAPER 1). After excluding women 
in the earlier years the magnitude of the effects were attenuated for all outcomes, 
but remained elevated.  In the years with better ascertainment of obesity, although 
the magnitude of the effect is lower when compared to the full cohort, the risk is still 
elevated for NICU admission (1.29 95%CI 1.11, 1.50), respiratory distress (RR 1.37 
95%CI 1.01 1.87), hypoglycemia (1.12 95%CI0.79, 1.58), birth injury (1.16 95%CI 
0.82, 1.64) and large for gestational age (RR 1.30 95%CI 1.02, 1.65). Changes in 
precision are due to a smaller number of outcomes.  Estimates from models that 
were not adjusted and partially adjusted for obesity are presented in Appendix 5. 
Because our result of an increased risk for respiratory distress and NICU 
admission with glyburide versus insulin differed most from the findings in trials and 
these outcomes are strongly associated with obesity, we used the array approach to 
estimate the ‘true’ RR for these two outcomes (Appendix 3-Figure A).  To estimate 
the ‘true’ RR we assumed that the association between obesity and initiating 
glyburide versus insulin (RR Glyb-O ) was  RR 1.38,  and the association between 
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obesity and respiratory distress (RR O-RDS) was 1.8, which are the magnitudes of 
effect observed  in our population . Using this approach the ‘true’ RR for respiratory 
distress would be 1.55 where the bias in our partially adjusted estimates would be 
approximately 5%. In scenarios where the magnitude for RR Glyb-O is larger, the 
‘true’ RR will be closer to 1.4 (holding RR O-RDS constant). For NICU admission, in 
our study the association between obesity and NICU (RR O-NICU) was 1.4. The 
‘true’ association between glyburide and NICU admission was 1.36  where bias in 
our partially adjusted estimates would be 2.8% (Appendix 5-Figure B).  
6.3 Discussion  
In our population- based cohort of 9,180 women with gestational diabetes we 
found evidence of an increased risk of adverse events in those treated with glyburide 
when compared to insulin. Admission to the NICU, respiratory distress, 
hypoglycemia, birth injury and large for gestational age were more likely to occur 
among women treated with glyburide. Smaller differences between treatment groups 
were found for outcomes such as obstetric trauma, cesarean section, jaundice or 
preterm birth. 
Previous literature on the association between treatment with glyburide and 
adverse neonatal outcomes is limited. To date, only three trials have assessed the 
safety or effectiveness of glyburide compared to insulin in pregnancy. The only 
outcomes reported by all trials were neonatal hypoglycemia and cesarean section 
(Figure 1).  All studies found an elevated risk of neonatal hypoglycemia but the 
magnitude of the effect differed (18, 19). When compared with the RCTs, the 
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magnitude of our estimated effect was lower which could be explained by 
differences in the definition of the outcome. Our study identified newborns with 
hypoglycemia who required care in the NICU, while trials identified hypoglycemia 
cases based on blood glucose measurements. Given the controversy regarding 
choice of cutoff values to diagnose and treat neonatal hypoglycemia, our estimate 
may be more reflective of symptomatic hypoglycemia.  
Only the trial by Langer et al reported estimates for outcomes such as NICU 
admission, respiratory distress and jaundice (17). Our findings differ from those 
published by Langer et al. for these outcomes. In their study the risk of NICU 
admission and respiratory distress was lower among newborns from glyburide 
treated women (RR 0.87 95%CI 0.41, 1.83 and RR=0.67 95%CI 0.19, 2.35, 
respectively ). However, the trial was a single-site study with a standardized protocol 
for maternal and newborn care.  Since criteria for admission to the NICU could vary 
across providers, our results could be more representative of practices related to 
newborn care across the United States. Compared to the trial our definition of 
respiratory distress identified critically ill infants and excluded less serious diagnoses 
such as transient tachypnea of the newborn. Therefore, our estimates for respiratory 
distress may be reflective of more severe conditions requiring NICU admission. The 
same principle applies to jaundice where the trial identified newborns based on 
predefined bilirubin cutoff values, while our study identified newborns with jaundice 
who required care in the NICU. 
The risk of large for gestational age was 43% higher among newborns from 
glyburide treated women. In our study this outcome was defined through the use of 
 52 
 
ICD9 codes. Because coding for this diagnosis may include both macrosomia or 
large for gestational age, our estimates could differ from those in trials. In the trials, 
large for gestational age had a prevalence of 5.7% (n=23) in the study by Langer, 
and  7.8% (n=4) in the study by Bertini. For macrosomia the prevalence was 
12.4%(n=50) and 13.7% (n=7) for the study by Langer and Bertini, respectively. The 
prevalence in our study was 4.0% (n=368), which is closer to the prevalence of 
macrosomia reported in the trials. Our estimate is of lower magnitude but consistent 
with the estimates for macrosomia reported by Langer (RR 1.57 95%CI 0.70, 3.55) 
and Bertini (RR 10.1 95%CI 0.57, 178.0 ).  
Birth injury and preterm birth were not assessed in the clinical trials. The 
observational studies by Jacobson et al. and Ramos et al. reported a higher risk of 
birth injury among those in the glyburide group (3.03 95%CI 0.81, 11.28; 3.55 95%CI 
0.33,38.0)(20, 24). Although their population was largely Hispanic and insured by 
Medicaid, our estimates are more modest when compared to their findings.  
Regarding preterm birth, our findings are consistent with those reported by Jacobson 
et al. who found no difference between treatment groups (RR 0.97 95%CI 0.61, 
1.54), but not with Ramos et al. who found an increased risk among women on 
glyburide (1.97 95%CI 0.87, 4.48). Given that by design the population in the study 
by Ramos had higher glucose values in both the screening and tolerance test, 
differences could be attributed to different risks across groups of women. 
Absence of information on BMI could lead to residual confounding by BMI. To 
assess the impact of partially adjusting for a known confounder (diagnostic code for 
obesity), we compared estimates from models not adjusted and partially adjusted for 
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obesity. For outcomes such as obstetric trauma, cesarean section, jaundice and 
preterm birth we observed not much difference between the three models. The effect 
of partially adjusting for obesity is more evident for outcomes such as NICU 
admission, respiratory distress, hypoglycemia and large for gestational age where 
the estimate shifts closer to the null. This may be explained by differences in the 
strength of the association between obesity and the outcome. This is graphically 
depicted in Appendix 5 where we observe what the ‘true’ association would be in 
scenarios where the prevalence of obesity in the glyburide group is increased or 
where the strength of the association between obesity and the outcome is varied . In 
both figures our estimates are close to the ‘true’ RRs for the ranges of obesity-
outcome association observed in our data, which are consistent with prior literature 
(REFS). In addition our findings are consistent with recent work published by Ogburn 
et al supporting the statement by Greenland in which adjusting for a binary 
mismeasured confounder reduces bias, but produces a measure of effect that lies 
between the crude and the true estimate (93). The underlying assumption is that the 
direction of the effect between the confounder and the outcome is the same for both 
treatment groups. There is no evidence to suggest that the effect of obesity on 
adverse outcomes would differ in women treated with glyburide versus insulin. 
To our knowledge, our study is the largest US population–based study to date 
to assess the comparative effectiveness of glyburide in pregnancy. Limitations of our 
study include lack of information on race-ethnicity, measurement error for obesity 
and the potential for unmeasured confounding. Previous studies have shown 
heterogeneity in the risk of adverse neonatal events by race. However there is no 
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evidence on differences by race after women initiate pharmacological treatment. 
Patterns observed in our dataset can be considered as representative of patterns of 
care among the employed and insured in the United States, providing an advantage 
over clinical trials. When compared to self-report, ascertainment of initiation of 
treatment through pharmacy claims is substantially improved, although we are 
unable to ascertain initial dosage and dosage escalation which affect glucose 
control. Because maternal and neonatal outcomes are relatively rare, large claims 
databases provide a unique setting to study safety and effectiveness of medications 
in pregnancy.   
Conclusion 
After accounting for maternal comorbidities and risk factors for neonatal 
outcomes we found an elevated risk for NICU admissions, neonatal hypoglycemia, 
respiratory distress, birth injury and large for gestational age in women with GDM 
treated with glyburide compared with insulin. These results are in agreement with 
findings from prior studies and suggest that women on glyburide may not be 
achieving adequate glucose control.  
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6.4 Tables and Figures 
Table 7. Baseline characteristics of women with gestational diabetes treated with 
pharmacotherapy, 2000-2011 
 
Insulin 
 
Glyburide 
 
 
N=4,194 % 
 
N=4,986 % %Δ* 
Age, year- Mean(SD) 34 (4.7) 
  
33 (4.8) 
  Age, 5y categories 
      15-19 4 0.1 
 
3 0.1 -0.04 
20-24 99 2.4 
 
124 2.5 0.13 
25-29 730 17.4 
 
940 18.9 1.45 
30-34 1593 38.0 
 
1860 37.3 -0.68 
35-39 1292 30.8 
 
1508 30.2 -0.56 
40-44 442 10.5 
 
523 10.5 -0.05 
>=45 34 0.8 
 
28 0.6 -0.25 
       Calendar year 
      2001 54 1.3 
 
5 0.1 -1.19 
2002 115 2.7 
 
20 0.4 -2.34 
2003 245 5.8 
 
73 1.5 -4.38 
2004 366 8.7 
 
188 3.8 -4.96 
2005 449 10.7 
 
306 6.1 -4.57 
2006 409 9.8 
 
374 7.5 -2.25 
2007 406 9.7 
 
538 10.8 1.11 
2008 438 10.4 
 
661 13.3 2.81 
2009 657 15.7 
 
1003 20.1 4.45 
2010 563 13.4 
 
928 18.6 5.19 
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2011 492 11.7 
 
890 17.8 6.12 
Region 
      Northeast 639 15.2 
 
525 10.5 -4.71 
Northcentral 1163 27.7 
 
1442 28.9 1.19 
South 1529 36.5 
 
1955 39.2 2.75 
West  838 20.0 
 
1037 20.8 0.82 
Unknown 25 0.6 
 
27 0.5 -0.05 
Comorbidities 
      Infertility treatment 283 6.7 
 
280 5.6 -1.13 
Hypothyroidism 349 8.3 
 
353 7.1 -1.24 
PCOS† 171 4.1 
 
162 3.2 -0.83 
Hyperandrogenism 67 1.6 
 
99 2.0 0.39 
Hyperprolactinemia 14 0.3 
 
11 0.2 -0.11 
Metabolic syndrome 30 0.7 
 
20 0.4 -0.31 
Obesity 305 7.3 
 
499 10.0 2.74 
Overweight 9 0.2 
 
17 0.3 0.13 
No comorbidities 3154 75.2 
 
3773 75.7 0.47 
Antihypertensive use  104 2.5 
 
143 2.9 0.39 
Preeclampsia hospitalization 219 5.2 
 
325 6.5 1.30 
       Metformin use 
      Any use before 1st Rx 293 7.0 
 
345 6.9 -0.07 
 
 
*%Δ –Difference in Percent  † PCOS- Polycystic ovarian syndrome 
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Table 8. Risk Ratios (RR) and 95% confidence intervals (95%CI) for adverse maternal and 
neonatal outcomes in women with GDM treated with glyburide compared to insulin 
 
No. Events 
 
Crude 
 
IPTW*-Adjusted 
 
Glyburide % Insulin % 
 
RR  95%CI 
 
RR  95%CI 
Obstetric 
trauma 111 2.2 102 2.4  
0.92 0.70, 1.19 
 
0.92 0.71, 1.20 
Cesarean 2,526 50.7 2,201 52.5 
 
0.97 0.93, 1.01 
 
0.97 0.93, 1.00 
NICU† 511 10.2 302 7.2 
 
1.42 1.24, 1.63 
 
1.39 1.21, 1.59 
Respiratory 
distress 145 2.9 73 1.7  
1.67 1.27, 2.21 
 
1.60 1.21, 2.11 
Hypo-
glycemia 95 1.9 55 1.3  
1.45 1.05, 2.02 
 
1.39 1.00, 1.94 
Jaundice 17 0.3 15 0.4 
 
0.95 0.48, 1.91 
 
0.94 0.47, 1.89 
Birth injury 111 2.2 69 1.6 
 
1.35 1.01, 1.82 
 
1.36 1.01, 1.84 
Preterm 474 9.5 371 8.8 
 
1.08 0.94, 1.22 
 
1.03 0.91, 1.18 
Large for 
Gestational 
Age 
234 4.7 134 3.2 
 
1.47 1.19, 1.81 
 
1.43 1.16, 1.76 
 
 
Risk Ratios are adjusted for infertility treatment, hypothyroidism, polycystic ovarian 
syndrome, hyperandrogenism, metabolic syndrome, obesity, antihypertensive use and 
preeclampsia, using inverse probability of treatment weights. Calendar year was adjusted 
for in the risk model. 
*IPTW-Inverse Probability of Treatment Weights 
†NICU- Neonatal intensive care unit- Admission for >24 h for newborns requiring support.  
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Table 9. Risk differences and 95% confidence intervals (95%CI) for adverse maternal and 
neonatal outcomes in women with GDM treated with glyburide compared to insulin 
 
No. Events 
  
Crude 
 
IPTW-Adjusted 
 
Glyburide % Insulin % 
 
RD 95%CI 
 
RD 95%CI 
Obstetric 
trauma 
111 2.2 102 2.4 
 
-0.21 -0.83, 0.42 
 
-0.19 -0.81, 0.43 
Cesarean 2,526 51 2,201 52 
 
-1.81 -3.87, 0.24 
 
-1.84 -3.89, 0.21 
NICU 511 10 302 7.2 
 
3.05 1.90, 4.20 
 
2.85 1.69, 4.00 
Respiratory 
distress 
145 2.9 73 1.7 
 
1.17 0.56, 1.78 
 
1.07 0.46, 1.68 
Hypo-
glycemia 
95 1.9 55 1.3 
 
0.59 0.08, 1.11 
 
0.53 0.02, 1.05 
Jaundice 17 0.3 15 0.4 
 
-0.02 -0.26, 0.23 
 
-0.02 -0.26, 0.22 
Birth injury 111 2.2 69 1.6 
 
0.58 0.02, 1.14 
 
0.60 0.03, 1.16 
Preterm 474 9.5 371 8.8 
 
0.66 -0.52, 1.85 
 
0.30 -0.89, 1.49 
LGA 234 4.7 134 3.2 
 
1.50 0.71, 2.29 
 
1.40 0.60, 2.20 
 
 
Risk Differences are adjusted for infertility treatment, hypothyroidism, polycystic ovarian 
syndrome, hyperandrogenism, metabolic syndrome, obesity, antihypertensive use and 
preeclampsia, using inverse probability of treatment weights. Calendar year was adjusted 
for in the risk model. 
*IPTW-Inverse Probability of Treatment Weights 
†NICU- Neonatal intensive care unit. 
‡LGA – Large for Gestational Age 
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Figure 6. Comparison of Risk Ratios and 95%CI between randomized controlled trials and the present study . 
 Glyburide Insulin  
    
Langer,2000 12/201 14/203 
Camelo,2013 511/4986 302/4194 
   
   
Langer,2000 4/201 6/203 
Camelo, 2013 145/4986 73/4194 
   
   
Langer,2000 18/201 12/203 
Bertini,2005 8/24 1/27 
Ogunyemi,2007 12/43 6/45 
Jacobson, 2005 72/236 73/268 
Camelo,2013 511/4986 302/4194 
   
Langer,2000 12/201 8/203 
Jacobson, 2005 59/236 58/268 
Camelo,2013 17/4986 15/4194 
   
Langer,2000 14/201 9/203 
Bertini,2005 4/24 0/27 
Jacobson, 2005 60/236 64/268 
Ramos, 2007 10/44 15/78 
Camelo,2013 234/4986 134/4194 
   
   
 
CHAPTER VII-DISCUSSION 
 
Prevalence of GDM has increased over the last decade, affecting 
reproductive age women across all ages. Due to the concomitant increase in insulin 
resistance and obesity, severity of the disease is also expected to be affected. One 
of the manifestations of severity is failure to achieve glucose control with 
interventions such as diet therapy and physical activity. Therefore the proportion of 
women that will require pharmacotherapy during pregnancy is expected to increase.   
This project focused on describing the dissemination of glyburide use and 
channeling of treatment, as well as examining the effectiveness of glyburide 
compared to insulin and adverse outcomes. Use of glyburide in pregnancy started 
only in the last decade and in the US the rate of use and factors driving its 
prescription are unknown. Our first aim addresses this issue by describing trends of 
use of glyburide as well as the identification of predictors of treatment with glyburide. 
After addressing factors that could influence choice of medication, we compared the 
effectiveness of glyburide versus insulin by estimating the risk of adverse events that 
direct or indirectly reflect achievement of glucose control. 
7.1 Summary of findings 
Over the 2000-2011 period the annual percent increase in the use of 
glyburide was 19.4%. While in 2001 only 8.5% of the women on pharmacotherapy 
initiated glyburide, since 2008 this percentage has increased over 60%. Identification 
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of predictors of treatment with glyburide included maternal comorbidities associated 
with insulin resistance such as hypothyroidism, metabolic syndrome, obesity and 
PCOS. Overall women initiating glyburide were younger and less likely to be insulin 
resistant or obese.  
Glucose values at screening or time of diagnosis (OGTT) do not seem to be 
associated with choice of medication. These results should be interpreted with 
caution since lab values were available for only a small proportion of women, and 
these women differed from the full cohort in their covariate distribution. Potentially 
glucose values at time of initiation are stronger predictors of drug class at initiation. 
 Because the distribution of comorbidities varied between treatment groups 
we used IPTW to adjust for confounding. After adjusting for covariates of interest our 
estimates showed an increased risk of admission to the NICU, hypoglycemia, 
respiratory distress, and large for gestational age among newborns from mothers 
treated with glyburide. We conducted sensitivity analysis to estimate the effect of 
women who were treated with glyburide in the early years, who may not be 
comparable to women treated after dissemination of treatment. Although the 
variability increased due to a reduction of the sample size, estimates of risk were 
consistent with previous results.  
Given that obesity is a strong risk factor and there is potential for 
measurement error we conducted additional sensitivity analysis to estimate the 
effect of residual confounding for NICU admission and respiratory distress. The 
analyses showed that under the conditions observed in the study where there are 
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10% more obese women in the glyburide group, our estimate of risk is only slightly 
biased. For our estimates to cross the null, the strength of the confounder outcome 
association would have to be extreme and the proportion of women with obesity in 
the glyburide group would have to be higher than 30%.   
7.2 Strengths and limitations 
Limitations of our study include absence of information on gestational age, 
under ascertainment of obesity and absence of information on race-ethnicity. Claims 
databases usually do not have person level information such as last menstrual 
period or biometrics (such as height, weight). Information on gestational age would 
allow us to identify start of pregnancy and therefore have better ascertainment of the 
pre-pregnancy period. This is relevant for the identification of comorbidities and 
exclusion criteria such as pre-gestational type 1 or 2 diabetes. Because we also 
excluded women who had a prescription for insulin or glyburide more than 150 days 
before delivery, we were likely to capture pre-gestational type 1 or 2 diabetics that 
were not identified using ICD9 codes. Our approach to identify GDM  is comparable 
to previously published validation studies where the misclassification due to absence 
of information on gestational age is small (87).   
We used ICD9 codes to ascertain obesity in our study. Because occurrence 
of codes is related to reimbursement, codes for obesity may be underutilized unless 
a procedure requiring the code is being billed for. Additionally, since 2006 new 
codes were included more specific to defined ranges of BMI. The use of these codes 
is expected to rise as reimbursement policies that require these codes start taking 
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place. Therefore we expect under ascertainment of obesity, especially before 2006. 
Even though our measure of obesity has error we do not expect it to be differential 
between treatment groups. Because our data is de-identified a validation study for 
obesity was not feasible. 
Racial and ethnic differences in treatment and risk of adverse outcomes have 
been described previously. Treatment may be affected by access to healthcare as 
well as individual preferences, or providers perception of risk. Additionally clinical 
characteristics of women with GDM, such as obesity, may vary across different 
races and ethnic groups. Heterogeneity across races in the response to 
pharmacological therapy along with interaction with other comorbidities may explain 
differences between groups. Due to absence of personal identifiers such as race, 
this issue was not explored and is outside the scope of this study.   
Strengths are ascertainment of medication use, sample size and 
generalizability. Ascertainment of medication use in administrative databases is 
thought to be more accurate than self-report. Because we were interested in 
initiation of medication and timing is key to identify ‘true’ GDM, pharmacy claims 
associated with prescription fills become reliable source to ascertain time of 
initiation. Our ability to address the effects of dose at initiation or dose escalation is  
limited due to absence of this information in the data.  
Among the RCTs and observational studies published to date, our study is 
the largest and most reflective of the use of glyburide and insulin for GDM at the 
population level. Because adverse maternal and neonatal outcomes are relatively 
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rare, a large sample size allows us to observe such outcomes. Given that our 
population is not hospital based we are more likely to capture differences in 
characteristics of women with GDM as well as variations in GDM management 
across the United States, which may impact outcomes. Our data are representative 
of higher density population areas which is reflected in the large proportion of 
women in urban settings. Overall our study population can be considered as being 
reflective of the US population.   
7.3 Public Health Implications 
We provide evidence on the widespread use of glyburide for the treatment of GDM 
in the US. Although use of glyburide was expected to increase throughout the 
decade, it has surpassed insulin as therapy of choice. Currently there are no 
available recommendations providing guidance for treatment with glyburide. A 
reflection of this is the absence of strong drivers for treatment with glyburide among 
covariates assessed in the study. It is possible that other factors such as personal 
preference, provider experience or perception of risk influence this decision. 
Additionally in other subgroups not included in this study, access to healthcare and 
cost of medications may also play an important role. 
A higher risk of neonatal outcomes among glyburide treated women demands 
further attention. Prevention of neonatal outcomes has short term impact in terms of 
morbidity and costs of care. In addition, recent studies have started to link metabolic 
disturbances in the neonatal period to the risk of insulin resistance or obesity in 
childhood or adulthood (94, 95). Clinically this implies that better management of 
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women treated with glyburide is needed. There is need for evidence based 
recommendations that provide guidance relative to dosing, and that help identify of 
women more likely to benefit from glyburide. 
7.4 Conclusions 
In conclusion we present evidence of higher risk of adverse outcomes in women with 
GDM treated with glyburide when compared to insulin, in the US.  Because 
dissemination of glyburide is high, clinicians should be aware of its effectiveness 
when compared to insulin. Closer follow-up after initiation of glyburide may allow 
earlier identification of women not benefiting from therapy. Design and 
implementation of guidelines for management of GDM with glyburide is a priority in 
this population. 
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APPENDIX 1. ICD9 and CPT codes used to identify deliveries 
 
Diagnosis Code Code type Description 
Delivery V27.0 ICD9 Single liveborn 
V27.9 ICD9 Unspecified outcome of deliver 
650 ICD9 Normal delivery 
 
 
Procedure Code Code type  Description 
Cesarean Section 59510 CPT Routine obstetric care including antepartum 
care, cesarean delivery and postpartum care 
59514 CPT Cesarean only 
59515 CPT Cesarean only, including postpartum care 
740 ICD9P Classical c-section 
741 ICD9P Low cervical c-section 
742 ICD9P Extraperitoneal c-section 
744 ICD9P C-section of other specified type 
749 ICD9P C-section unspecified type 
7499 ICD9P Other c-section 
Vaginal 
59400 CPT 
Routine obstetric care, vaginal del (w-w/o 
episiotomy or forceps) and postpartum care 
59409 CPT 
Vaginal del only (w-w/o episiotomy or 
forceps)  
59410 CPT Vaginal del only + postpartum care 
59412 CPT External cephalic version 
Vaginal after 
previous cesarean 
59610 CPT 
Routine obstetric care including antepartum 
care, cesarean delivery and postpartum 
care, after previous cesarean delivery 
59612 CPT 
Vaginal del only after previous c-section (w-
w/o episiotomy or forceps)  
59614 CPT 
Vaginal del only after previous c-section (w-
w/o episiotomy or forceps) , including 
postpartum care 
59618 CPT 
Routine obstetric care including antepartum 
care, cesarean delivery and postpartum 
care, following attempted vaginal del, after 
previous cesarean delivery 
59620 CPT 
Cesarean del only, following attempted vag 
del after prev c-section 
59622 CPT 
Cesarean del only, following attempted vag 
del after prev c-section; including postpartum 
care 
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APPENDIX 2- ICD9 and CPT codes used to identify outcomes 
 
Obstetric 
Trauma 
664.2 ICD9 Third-degree perineal laceration 
 664.20 ICD9 Third-degree perineal laceration 
unspecified as to episode of care or not applicable 
 664.21 ICD9 Third-degree perineal laceration 
delivered, with or without mention of antepartum 
condition 
 664.24 ICD9 Third-degree perineal laceration 
postpartum condition or complication 
 664.3 ICD9 Fourth-degree perineal laceration 
 664.30 ICD9 Fourth-degree perineal laceration 
unspecified as to episode of care or not applicable 
 664.31 ICD9 Fourth-degree perineal laceration 
delivered, with or without mention of antepartum 
condition 
 664.34 ICD9 Fourth-degree perineal laceration 
postpartum condition or complication 
 665 ICD9 Other obstetrical trauma 
 665.3 ICD9 Laceration of cervix 
 665.30 ICD9 Laceration of cervix 
unspecified as to episode of care or not applicable 
 665.31 ICD9 Laceration of cervix 
delivered, with or without mention of antepartum 
condition 
 665.34 ICD9 Laceration of cervix 
postpartum condition or complication 
 665.4 ICD9 High vaginal laceration 
 665.41 ICD9 High vaginal laceration 
delivered, with or without mention of antepartum 
condition 
 665.44 ICD9 High vaginal laceration 
postpartum condition or complication 
 75 ICD9P Other obstetric operations 
 75.5 ICD9P Repair of current obstetric laceration of uterus 
 75.50 ICD9P Repair of current obstetric laceration of uterus, not 
otherwise specified 
 75.51 ICD9P Repair of current obstetric laceration of cervix 
 75.52 ICD9P Repair of current obstetric laceration of corpus uteri 
 75.6 ICD9P Repair of other current obstetric laceration 
 75.61 ICD9P Repair of current obstetric laceration of bladder and 
urethra 
 75.62 ICD9P Repair of current obstetric laceration of rectum and 
sphincter ani 
 75.69 ICD9P Repair of other current obstetric laceration 
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Cesarean 59510 CPT Routine obstetric care including antepartum care, 
cesarean delivery and postpartum care 
 59514 CPT Cesarean only 
 59515 CPT Cesarean only, including postpartum care 
 740 ICD9P Classical c-section 
 741 ICD9P Low cervical c-section 
 742 ICD9P Extraperitoneal c-section 
 744 ICD9P C-section of other specified type 
 749 ICD9P C-section unspecified type 
 7499 ICD9P Other c-section 
 
59618 CPT 
Routine obstetric care including antepartum care, 
cesarean delivery and postpartum care, following 
attempted vaginal del, after previous cesarean 
delivery 
 
59620 CPT 
Cesarean del only, following attempted vag del after 
prev c-section 
 
59622 CPT 
Cesarean del only, following attempted vag del after 
prev c-section; including postpartum care 
 
NICU 
admission 
99295 CPT First day of NICU , neborns 
 99468 CPT Critical care code – Initial day 
 99477 CPT Intensive care services- Initial day neonates 
 
Respiratory 
Distress 
770.84 ICD9 Respiratory failure of newborn 
 770.87 ICD9 Respiratory arrest of newborn 
 770.89 ICD9 Other respiratory problems after birth 
 770.9 ICD9 Unspecified respiratory condition of fetus and 
newborn 
 
Hypo-
glycemia 
775.6 ICD9 Neonatal Hypoglycemia 
 775.0 ICD9 Syndrome of Infant of diabetic mother 
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Jaundice 36450 CPT Exchange transfusion blood, newborn 
 9983 ICD9P Phototherapy (bilirubin) light with photometer 
 9982 ICD9P Phototherapy (bilirubin) -uv 
 7741 ICD9 Othe jaundice from excessive hemolysis 
 7745 ICD9 Perinatal jaundice from other causes 
 7746 ICD9 Unspecified fetal and neonatal jaundice 
 
Birth 
Trauma 
653.4 ICD9  Fetopelvic disproportion 
 653.41 ICD9  Fetopelvic disproportion 
delivered, with or without mention of antepartum 
condition 
 653.42 ICD9  Fetopelvic disproportion 
delivered, with mention of postpartum complication 
 653.44 ICD9  Fetopelvic disproportion 
postpartum condition or complication 
 653.5 ICD9  Unusually large fetus causing disproportion 
 653.51 ICD9  Unusually large fetus causing disproportion 
delivered, with or without mention of antepartum 
condition 
 653.52 ICD9  Unusually large fetus causing disproportion 
delivered, with mention of postpartum complication 
 660.4 ICD9  Shoulder (girdle) dystocia 
 660.41 ICD9  Shoulder (girdle) dystocia 
delivered, with or without mention of antepartum 
condition 
 660.42 ICD9  Shoulder (girdle) dystocia 
delivered, with mention of postpartum complication 
 660.44 ICD9  Shoulder (girdle) dystocia 
postpartum condition or complication 
 767 ICD9  Birth trauma 
 767.0 ICD9  Subdural and cerebral hemorrhage 
 767.1 ICD9  Injuries to scalp 
 767.11 ICD9  Epicranial subaponeurotic hemorrhage (massive) 
 767.19 ICD9  Other injuries to scalp 
 767.2 ICD9  Fracture of clavicle 
 767.3 ICD9  Other injuries to skeleton 
 767.4 ICD9  Injury to spine and spinal cord 
 767.5 ICD9  Facial nerve injury 
 767.6 ICD9  Injury to brachial plexus 
 767.7 ICD9  Other cranial and peripheral nerve injuries 
 767.8 ICD9  Other specified birth trauma 
 767.9 ICD9  Birth trauma, unspecified 
 959 ICD9  Injury, other and unspecified 
 70 
 
 959.0 ICD9  Head, face and neck 
 959.01 ICD9  Head injury, unspecified 
 959.09 ICD9  Injury of face and neck 
 959.1 ICD9  Trunk 
 959.11 ICD9  Other injury of chest wall 
 959.12 ICD9  Other injury of abdomen 
 959.13 ICD9  Fracture of corpus cavernosum penis 
 959.14 ICD9  Other injury of external genitals 
 959.19 ICD9  Other injury of other sites of trunk 
 959.2 ICD9  Shoulder and upper arm 
 959.3 ICD9  Elbow, forearm, and wrist 
 959.4 ICD9  Hand, except finger 
 959.5 ICD9  Finger 
 959.6 ICD9  Hip and thigh 
 959.7 ICD9  Knee, leg, ankle, and foot 
 959.8 ICD9  Other specified sites, including multiple 
 959.9 ICD9  Unspecified site 
 
Preterm 765.1 ICD9 Other preterm infants 
 765.10 ICD9 Other preterm infants 
unspecified [weight] 
 765.11 ICD9 Other preterm infants 
less than 500 grams 
 765.12 ICD9 Other preterm infants 
500-749 grams 
 765.13 ICD9 Other preterm infants 
750-999 grams 
 765.14 ICD9 Other preterm infants 
1,000-1,249 grams 
 765.15 ICD9 Other preterm infants 
1,250-1,499 grams 
 765.16 ICD9 Other preterm infants 
1,500-1,749 grams 
 765.17 ICD9 Other preterm infants 
1,750-1,999 grams 
 765.18 ICD9 Other preterm infants 
2,000-2,499 grams 
 765.19 ICD9 Other preterm infants 
2,500 grams and over 
 765.21 ICD9 Less than 24 completed weeks of gestation 
 765.22 ICD9 24 weeks of gestation 
 765.23 ICD9 25-26 weeks of gestation 
 770.84 ICD9 Respiratory failure of newborn 
 770.87 ICD9 Respiratory arrest of newborn 
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 770.89 ICD9 Other respiratory problems after birth 
 770.9 ICD9 Unspecified respiratory condition of fetus and 
newborn 
 
LGA 766.0 ICD9 Exceptionally large baby 
 7661 ICD9 Other heavy for dates infants 
 656.6 ICD9 Excessive fetal growth 
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APPENDIX 3- Characteristics of women with laboratory results, 2007-2011 
 
 
Insulin 
 
Glyburide 
 
 
N=115 % 
 
N=224 % %Δ 
Age, year- Mean(SD) 35 (4.9) 
  
34 (4.8) 
  Age, 5y categories 
      15-19 3 2.6 
 
8 3.6 1.0 
20-24 18 15.7 
 
34 15.2 -0.5 
25-29 33 28.7 
 
72 32.1 3.4 
30-34 48 41.7 
 
80 35.7 -6.0 
35-39 22 19.1 
 
28 12.5 -6.6 
40-44 2 1.7 
 
2 0.9 -0.8 
>=45 
 
0.0 
 
0 0.0 0.0 
Calendar year 
      2007 7 6.1 
 
5 2.2 -3.9 
2008 7 6.1 
 
28 12.5 6.4 
2009 43 37.4 
 
63 28.1 -9.3 
2010 32 27.8 
 
72 32.1 4.3 
2011 26 22.6 
 
56 25.0 2.4 
Region 
      Northeast 17 14.8 
 
19 8.5 -6.3 
Northcentral 17 14.8 
 
38 17.0 2.2 
South 63 54.8 
 
130 58.0 3.3 
West  18 15.7 
 
37 16.5 0.9 
Unknown 0 0.0 
 
0 0.0 0.0 
Comorbidities 
      Infertility treatment 7 6.1 
 
7 3.1 -3.0 
Hypothyroidism 15 13.0 
 
23 10.3 -2.8 
PCOS 6 5.2 
 
7 3.1 -2.1 
Hyperprolactinemia 1 0.9 
 
1 0.4 -0.4 
Hyperandrogenism 2 1.7 
 
2 0.9 -0.8 
Metabolic syndrome 1 0.9 
 
1 0.4 -0.4 
Obesity 22 19.1 
 
42 18.8 -0.4 
overweight 0 0.0 
 
2 0.9 0.9 
No comorbidities 74 64.3 
 
154 68.8 4.4 
Metformin use 
      Any Use before first RX 6 5.2 
 
17 7.6 2.4 
 
 
*Difference in percentage (Δ%)-Estimated by subtracting percentages in insulin column from 
glyburide. †PCOS- Polycystic Ovarian Syndrome 
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Crude 
 
IPTW-Adjusted 
   
N 
No.
Events 
 
RR  95%CI 
 
RR  95%CI 
Obstetric 
trauma 
No exclusion Glyburide 4986 111   0.92 0.70   1.19   0.92 0.71   1.20 
 
Insulin 4194 102 
          2004-2011 Glyburide 4884 107 
 
1.00 0.75 
 
1.32 
 
1.00 0.75 
 
1.33 
 
Insulin 3777 83 
          2005-2011 Glyburide 4696 101 
 
1.02 0.76 
 
1.37 
 
1.02 0.75 
 
1.37 
 
Insulin 3411 72 
          2007-2011 Glyburide 4020 87 
 
1.01 0.72 
 
1.40 
 
0.99 0.71 
 
1.39 
 
Insulin 2556 55 
          
Cesarean 
No exclusion Glyburide 4986 2526   0.97 0.93   1.01   0.97 0.93   1.00 
 
Insulin 4194 2201 
          2004-2011 Glyburide 4884 2476 
 
0.96 0.92 
 
1.00 
 
0.97 0.93 
 
1.01 
 
Insulin 3777 1987 
          2005-2011 Glyburide 4696 2390 
 
0.96 0.92 
 
1.00 
 
0.96 0.92 
 
1.00 
 
Insulin 3411 1813 
          2007-2011 Glyburide 4020 2041 
 
0.95 0.90 
 
0.99 
 
0.96 0.91 
 
1.00 
  Insulin 2556 1370                     
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Crude 
 
IPTW-Adjusted 
   
N 
No.
Events 
 
RR  95%CI 
 
RR  95%CI 
NICU 
No exclusion Glyburide 4986 511   1.42 1.24   1.63   1.39 1.21   1.59 
 
Insulin 4194 302 
          2004-2011 Glyburide 4884 503 
 
1.37 1.19 
 
1.57 
 
1.34 1.17 
 
1.55 
 
Insulin 3777 284 
          2005-2011 Glyburide 4696 494 
 
1.36 1.18 
 
1.57 
 
1.34 1.16 
 
1.55 
 
Insulin 3411 264 
          2007-2011 Glyburide 4020 458 
 
1.30 1.12 
 
1.51 
 
1.29 1.11 
 
1.50 
 
Insulin 2556 224 
          
Respiratory 
distress 
No exclusion Glyburide 4986 145   1.67 1.27   2.21   1.60 1.21   2.11 
 
Insulin 4194 73 
          2004-2011 Glyburide 4884 143 
 
1.56 1.18 
 
2.06 
 
1.50 1.13 
 
1.99 
 
Insulin 3777 71 
          2005-2011 Glyburide 4696 140 
 
1.54 1.15 
 
2.06 
 
1.49 1.11 
 
2.00 
 
Insulin 3411 66 
          2007-2011 Glyburide 4020 127 
 
1.39 1.02 
 
1.89 
 
1.37 1.01 
 
1.87 
  Insulin 2556 58                     
Hypoglycemia 
No exclusion Glyburide 4986 95   1.45 1.05   2.02   1.39 1.00   1.94 
 
Insulin 4194 55 
          2004-2011 Glyburide 4884 95 
 
1.39 0.99 
 
1.93 
 
1.34 0.96 
 
1.87 
 
Insulin 3777 53 
          2005-2011 Glyburide 4696 94 
 
1.34 0.95 
 
1.88 
 
1.30 0.93 
 
1.83 
 
Insulin 3411 51 
          2007-2011 Glyburide 4020 88 
 
1.14 0.81 
   
1.12 0.79 
 
1.58 
 
Insulin 2556 49 
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Crude 
 
IPTW-Adjusted 
   
N 
No.
Events 
 
RR  95%CI 
 
RR  95%CI 
Jaundice 
No exclusion Glyburide 4986 17   0.95 0.48   1.91   0.94 0.47   1.89 
 
Insulin 4194 15 
          2004-2011 Glyburide 4884 17 
 
0.94 0.46 
 
1.90 
 
0.94 0.46 
 
1.91 
 
Insulin 3777 14 
          2005-2011 Glyburide 4696 17 
 
0.95 0.46 
 
1.95 
 
0.95 0.46 
 
1.95 
 
Insulin 3411 13 
          2007-2011 Glyburide 4020 17 
 
0.83 0.40 
 
1.71 
 
0.83 0.40 
 
1.71 
 
Insulin 2556 13 
          
Birth injury 
No exclusion Glyburide 4986 111   1.35 1.01   1.82   1.36 1.01   1.84 
 
Insulin 4194 69 
          2004-2011 Glyburide 4884 111 
 
1.32 0.98 
 
1.79 
 
1.32 0.98 
 
1.80 
 
Insulin 3777 65 
          2005-2011 Glyburide 4696 104 
 
1.30 0.95 
 
1.79 
 
1.31 0.95 
 
1.81 
 
Insulin 3411 58 
          2007-2011 Glyburide 4020 90 
 
1.17 0.83 
 
1.65 
 
1.16 0.82 
 
1.64 
 
Insulin 2556 49 
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Crude 
 
IPTW-Adjusted 
   
N 
No.
Events 
 
RR  95%CI 
 
RR  95%CI 
Preterm 
No exclusion Glyburide 4986 474   1.08 0.94   1.22   1.03 0.91   1.18 
 
Insulin 4194 371 
          2004-2011 Glyburide 4884 463 
 
1.08 0.95 
 
1.24 
 
1.04 0.91 
 
1.19 
 
Insulin 3777 331 
          2005-2011 Glyburide 4696 442 
 
1.06 0.92 
 
1.22 
 
1.03 0.89 
 
1.18 
 
Insulin 3411 303 
          2007-2011 Glyburide 4020 391 
 
1.09 0.93 
 
1.27 
 
1.06 0.91 
 
1.24 
 
Insulin 2556 228 
          
Large for 
Gestational Age 
No exclusion Glyburide 4986 234   1.47 1.19   1.81   1.43 1.16   1.76 
 
Insulin 4194 134 
          2004-2011 Glyburide 4884 228 
 
1.39 1.12 
 
1.72 
 
1.36 1.10 
 
1.68 
 
Insulin 3777 127 
          2005-2011 Glyburide 4696 221 
 
1.34 1.08 
 
1.66 
 
1.31 1.05 
 
1.63 
 
Insulin 3411 120 
          2007-2011 Glyburide 4020 200 
 
1.32 1.04 
 
1.68 
 
1.30 1.02 
 
1.65 
 
Insulin 2556 96 
           
In the 2007-2011 cohort we estimated the effect of treatment with glyburide on maternal and neonatal outcomes with obesity treated 
as an unmeasured confounder. To do this we excluded obesity from the propensity score model and estimated inverse probability of  
treatment weights. We used these weights to adjust for other confounders in the model and estimated Risk Ratios and 95%CIs.  
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APPENDIX 5- Sensitivity analysis: Unmeasured confounding   
 
In the 2007-2011 cohort we estimated the effect of treatment with glyburide on respiratory 
distress and NICU admission with obesity treated as an unmeasured confounder. To do this 
we excluded obesity from the propensity score model and estimated inverse probability of 
treatment weights. We used these weights to adjust for other confounders in the model and 
estimated the effect on respiratory distress (RRRDS) and NICU admission (RRNICU). The 
results from these analysis are depicted in Figures A and B. We compared estimates 
obtained from the unmeasured confounding model with estimates obtained in our fully 
adjusted model. 
 
 
Figure A- Respiratory distress: in the unmeasured confounder scenario the apparent 
relative risk for respiratory distress (ARRRDS) is 1.63, when the proportion of obesity is equal 
among treatment groups. If the prevalence of obesity increases in the glyburide group then 
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the  ARRRDS will shift towards the null. The decline of the ARRRDS  will be steeper as the 
strength of the association between obesity and respiratory distress increases (RRO-RDS). 
The red square represents the RR estimate from the adjusted model that included obesity in 
the propensity score. Based on previously published studies it is unlikely that the prevalence 
of obese women in the glyburide group would be more than two times the prevalence in the 
insulin group. 
 
 
Figure B- NICU admission- the apparent relative risk for NICU admission (ARRNICU) is 1.40, 
which is the observed effect in our study when obesity is not accounted for in the propensity 
score.  As the prevalence of obesity increases in the glyburide group (RR Obesity-Glyb), ARRNICU 
shifts towards the null. This shift is steeper when the magnitude of RRO-NICU is higher.Our 
adjusted estimate (RR adj)  is represented by the red square (RRGlyb-O=1.38). 
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